





SEX DIFFERENCES AND THE ROLE OF ESTROGEN, ESTROUS CYCLE, 






SUBMITTED TO THE FACULTY OF  













IN PARTIAL FULFILLMENT OF THE REQUIREMENTS 
FOR THE DEGREE OF  





Dr. Alvin J. Beitz 
& 










































© Jennifer L. Triemstra 2014 
 
   
Acknowledgements 
 
I would like to thank my advisors, Dr. Alvin J. Beitz and Dr. Alice A. Larson for 
their tireless mentorship and commitment towards my successful completion of 
this work.  I look forward to our future collaborations.  I would like to thank my 
thesis committee, Drs. Laura Mauro, Scott O’Grady, & Lucy Vulchanova-Hart, for 
always having an open door and an open mind for sharing thoughts and ideas 
that helped steer this work in the right direction.  Thank you to the entire CMB 
department and PNI training group, especially Lisa Hubinger, Jaci Barnes, and 
Yorie Smart.  I also want to thank all of my family and friends who stood by me 
and encouraged me through this process.  Finally, I want to thank my wife, 
Christine, who moved from sunny California to snowy Minnesota to support me 
as I fulfilled my dream of becoming a scientist. 
i
 ii 
TABLE OF CONTENTS 
 
List of Figures         iv 
List of Tables         v 
 
Chapter 1: Background and Research Overview        1 
Cancer prevalence and pain           2 
Pathophysiology of bone metastasis          3 
Sex differences in cancer pain           5 
Estrogens and pain             7 
Animal models of bone cancer pain        10 
TRP receptors and cancer pain         12  
Overview of Thesis           17 
Chapter 2:  Effects of Chronic Estrogen on Bone Cancer Pain  
in a Rodent Model: Sex Differences, Estrogen Receptors, and  
the Estrous Cycle           19 
Introduction            20 
Methods            22 
Results            30 
Discussion            34 
  
 iii 
Chapter 3:  Estrogen Effects on Bone Cancer Pain in a Rodent  
Model: Sex Differences, TRPA1 and TRPM8, and Menthol- 
Induced Antinociception          44 
Introduction            45 
Methods            48 
Results            57 
Discussion            61 
Chapter 4:  Sex Differences and Estrogen Effects on TRPV1 Expression  
and Antagonism in a Mouse Model of Bone Cancer Pain     70 
Introduction            71 
Methods            74 
Results            84 
Discussion            88 
Chapter 5:  Summary and Conclusions       96 
Summary            97 
Conclusions          103 
Chapter 6:  Literature Cited       107 
  
 iv 
LIST OF FIGURES  
 
Chapter 2:  Effects of Chronic Estrogen on Bone Cancer Pain in a Rodent 
Model: Sex Differences, Estrogen Receptors, and the Estrous Cycle  
Figure 1.  Tumor-induced mechanical allodynia      41 
Figure 2.  Tumor-induced mRNA expression       42 
Figure 3.  Correlational analysis of mechanical allodynia and relative  
mRNA expression.           43 
 
Chapter 3:  Estrogen Effects on Bone Cancer Pain in a Rodent Model: Sex 
Differences, TRPA1 and TRPM8, and Menthol-Induced Antinociception 
Figure 1.  Estrogen affects tumor-induced mechanical allodynia    66 
Figure 2.  Females are more sensitive to cold nociception     67 
Figure 3.  Tumor-induced TRP mRNA expression      68 
Figure 4.  Menthol reduces tumor-induced nociception     69 
 
Chapter 4:  Sex Differences and Estrogen Effects on TRPV1 Expression  
and Antagonism in a Mouse Model of Bone Cancer Pain 
Figure 1.  Estrous cycle affects mechanical allodynia but not thermal 
hyperalgesia.           92 
Figure 2.  17-estradiol replacement effects nociception in gonadectomized 
mice.             93 
 v 
Figure 3.  Estrous cycle and estrogen affects the tumor-induced TRPV1 mRNA 
expression in females.          94 
Figure 4.  JNJ-17203212, a TRPV1 antagonist, reduces tumor-induced 
hyperalgesia.           95 
 
LIST OF TABLES 
 
Chapter 2:  Effects of Chronic Estrogen on Bone Cancer Pain in a Rodent 
Model: Sex Differences, Estrogen Receptors, and the Estrous Cycle  
Table.  Ankle tumor size          40 
 
Chapter 5:  Summary and Conclusions 
Table.  Summary of findings across experimental groups   106 
 
 
   
Chapter 1 
 
Background and Research Overview 
  
1
   
Cancer Prevalence and Pain 
Cancer is second only to heart disease as a cause of mortality in the United 
States accounting for nearly 1 of every 4 deaths. According to the American 
Cancer Society over 1.5 million new cancer cases are expected to be diagnosed 
this year in the United States with over 500,000 patients projected to succumb to 
the disease [124].  With more than 10 million people diagnosed with cancer 
world-wide every year, it is projected that by 2020 this will have increased to 15 
million new cases each year [16].  Cancer patients can experience a number of 
symptoms that include fatigue, lack of energy, weight loss, nausea, difficulty 
breathing, pain, anxiety, depression and problems sleeping [9].  Pain may be the 
first symptom that causes someone to seek medical advice that leads to a 
diagnosis of cancer.  In cancer patients, pain may be caused by tumor 
progression and invasion, systemic treatments, cancer-related infections, and 
may involve inflammatory, neuropathic, ischemic, and compression mechanisms 
at multiple sites [68]. Although pain can occur at any time as the disease 
progresses, the frequency and intensity of pain tends to increase as the cancer 
advances.  Compounding the complexity of treatment of patients with advanced 
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cancers is the development of bone metastases which occur in 65–80% of 
cancer patients with advanced cancer [28; 71].  Due to improved tumor control, 
patients are living longer with cancer thus increasing their susceptibility to bone 
metastases and as such, increasing the susceptibility to cancer pain that 
interferes with their daily living [50; 104].   A more thorough understanding of 
these mechanisms would certainly provide a foundation for the development of 
treatment regimens that can successfully relieve cancer pain in the majority of 
advanced cancer patients.  However we are really in our infancy in terms of 
understanding the myriad molecular, cellular and systemic mechanisms that 
underlie the development and progression of cancer pain.  The fact that bone 
cancer is so prevalent and represents one of the most painful types of cancer 
has lead us to focus on bone cancer in the studies summarized in this thesis. 
 
Pathophysiology of bone metastasis 
Bone cancer pain most commonly occurs when tumors originating in breast, 
prostate, or lung metastasize to long bones, spinal vertebrae, and/or pelvis. The 
development of bone metastases begins when primary tumor cells transverse the 
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walls of small blood vessels and enter circulation to transverse the wide-
channeled sinusoids of the bone-marrow cavity.  Tumor growth stimulates the 
activity of osteoclasts and osteoblasts, increases inflammatory markers and 
growth factors, reduces pH, and increases angiogenesis [28; 56; 116].  Tumor-
induced bone remodeling enhances tumor growth and bone invasion, in turn 
creating devastating consequences on bone remodeling.  These consequences 
include pathological bone fractures, pain, hypercalcaemia, and spinal cord and 
nerve-compression syndromes [65; 88; 89].  Bone metastases are usually 
associated with severe bone pain, which can be intractable [50].  Fluctuations in 
bone pain, called breakthrough pain, are transient spikes in pain often evoked by 
movement [105].  Since advances in cancer therapy are increasing life 
expectancy of the patient, the threat of severe pain can compromise the patient’s 
quality of live.  A reduction in pain levels can enhance mobility, in turn, 
strengthening bones to prevent further fractures, improve nutrition and enhance 
the quality of life and promote improved survival.  
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The guidelines of the World Health Organization's opioid analgesic ladder report 
cancer pain relief should be adequate in 75-90% of patients [138].  However, it 
has been reported that 45% of cancer patients have inadequate and 
undermanaged pain control [43; 46].  This inadequate pain treatment is due to 
various factors including incomplete implementation of the guidelines perhaps 
due to treatment-associated side effects.  Opioids have adverse affects on 
various physiological functions including nausea, gastrointestinal motility, and 
suppressed respiratory activity [10].  Another major confound in treatment of 
cancer pain are discrepancies in analgesic treatment based on the sex of the 
cancer patient.  
 
Sex differences in cancer pain 
Sex plays a role in the vulnerability of humans to pain in experimentally-induced 
pain and in their sensitivity to analgesics [37; 46; 47; 49; 57].  The importance of 
sex differences in both acute and chronic pain conditions is demonstrated by the 
fact that women have a higher prevalence of several clinical and chronic pain 
conditions including fibromyalgia, arthritis, migraine, temporomandibular 
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disorders, and irritable bowel syndrome [48] [49]  Some debate still exists in the 
literature regarding sex differences in patients with cancer pain.  Early reports 
failed to find sex differences in cancer pain [28; 137] but more recent studies 
reveal that sex differences do exist [18; 71].  Women are more likely to 
experience enhanced cancer pain due to reduced treatment with analgesics [93] 
leading to a lower quality of life compared to their male counterparts [56]. 
 
It is known that there are sex differences in cancer diagnosis with premenopausal 
women at greater risk to develop cancer compared to men of the same age [4]   
This reverses after menopause with men being at greater risk to develop cancer 
compared to women.  Male and female cancer rates therefore intersect around 
the age of the menopause and this phenomenon remains stable over time.  The 
sex differences in cancer incidence could be attributed to the sex differences in 
hormonal status.  Moreover, approximately 70% of cancer diagnoses are either 
lung, breast, or prostate cancer [16].  In the latter two cases, hormone status can 
exacerbate tumor growth due to the involvement of hormone-sensitive tissue [44; 
51]. Overall, basic and clinical studies are just beginning to reveal the full extent 
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of sex differences in patients with cancer pain.  A major focus of sex difference 
research is delineating the role of sex steroid hormones, specifically estrogens, 
involvement in cancer pain. 
  
Estrogens and pain 
When examining sex differences, effects of gonadal hormones are a major focus 
of research [8; 57].  Fluctuations in female hormones over the menstrual cycle 
correspond with changes in pain perception [39; 41; 49; 107; 112; 113].  
Estrogens are considered a critical factor in sex-dependent differences in pain, 
where they have a complex role in inflammatory processes and pain responses 
[2; 49; 115; 118], reviewed in [25].    Estrogens exert effects by acting on two 
classic estrogen receptors, ERα and ERβ, which are widely expressed 
throughout the spinal cord and dorsal root ganglion of both males and females 
[75; 99; 133; 139] where levels of expression fluctuate depending on endocrine 
status.  Estrogens can act on ERs located in the plasma membrane or located in 
the nucleus [13].  Plasma membrane ERs also include a G protein coupled 
receptor (GPR30), which unlike ERα and ERβ, does not change with hormonal 
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rhythms [85].  Membrane ER activation initiates a spectrum of intracellular 
signaling cascades [26; 90] and modulates neuronal membrane excitability by 
gating calcium currents producing a myriad of effects on nociception and 
antinociception [15; 26; 27; 35].   Estrogen receptors are located in dorsal root 
ganglion (DRG) neurons [99], thus suggesting estrogens acting at either the 
nucleus or on cell membranes can modulate a broad array of physiological 
functions in these cells including those involved in the pathophysiology of pain.  
 
Estrogens have both pronociceptive and antinociceptive effects in a variety of 
animal models of pain.  Estradiol is pronociceptive as it enhances capsaicin-
induced acute pain in female rats [87] and potentiates sensitivity to colorectal 
distention [63].  Similarly, progesterone and estrogen receptor activation 
increases neuropathic pain in a mouse model of spinal nerve injury [72; 80]. 
Conversely, progesterone and estrogen receptor activation are antinociceptive in 
inflammatory models of pain in rats [63] [74].  Moreover, increases in estradiol 
concentration enhanced opioid antinociception in female rats [73; 127], and 
reversed thermal and mechanical hyperalgesia in ovariectomized rats [117] and 
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acted as an analgesic in a rat model of calculosis [1]. In cultures of DRG 
neurons, estradiol, acting on membrane receptors, attenuated ATP induced 
calcium currents [26] and eliminated the translocation and activation of PKCε in 
response to β-adrenergic receptor activation [62].  These in vitro findings suggest 
that estradiol modulates DRG excitability.  Whether estrogens and their receptors 
play a role in sex differences linked to cancer pain has yet to be determined. 
 
Additional research is needed to clarify the underlying mechanisms of sex 
differences in pain to facilitate the development of new treatment modalities that 
improve cancer pain management for both men and women.   The challenges 
facing new strategies to relieve cancer pain are multifaceted.  One major limiting 
factor has been the lack of basic knowledge of the neurobiology of cancer pain.  
Until recently, interpretation of cancer pain modalities was limited to animal 
models of painful conditions other than cancer.  Over the past decade, animal 
models of cancer pain have been developed and have begun to provide insight 
into the pathophysiology of bone cancer pain.  These models are now available 
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to provide important information surrounding the mechanisms underlying sex 
differences in cancer pain. 
 
Animal models of bone cancer pain 
One of the first animal models of bone cancer pain involved the implantation of 
fibrosarcoma  cells (NCTC 2472; derived from a spontaneous connective tissue 
tumor) into the medullary cavity of the femur or into the calcaneous bone of the 
hindpaw of C3H/He mice [19; 20; 140].  Implantation of NCTC 2472 tumor-
inducing cells produces a bone cancer model with behavioral, cellular, and 
neurochemical changes that can be correlated with tumor growth and bone 
destruction within 21 days of cell implantation. Mice implanted with NCTC 2472 
tumor cells exhibit nocifensive behavioral responses, including mechanical and 
thermal allodynia responses, that correlate with osteoclast bone destruction [19; 
141].  With this animal model of bone cancer pain, initial studies show that tumor 
growth is associated with the release of inflammatory mediators that excite and 
sensitize nociceptors (e.g. substance P, NGF, osteoprotegerin ligand and 
interleukin-10), while tumor growth alters the morphology of peripheral nerve 
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fibers, leading to a shift in the nociceptive responses of primary afferent neurons 
[21; 122].   
 
Primary afferent neuron perikarya are located in the DRG whose nerve fibers 
include unmyelinated C-fibers and thinly-myelinated Aδ-fibers that arise from cell 
bodies that are 15–45 µm in diameter.  The single axon bifurcates into a 
peripheral branch that innervates peripheral target tissue and a central branch 
that enters the CNS to synapse on second order neurons.  As tumor cells grow 
within and around the bone, the tumor impinges on surrounding tissue creating 
degradation and compression of peripheral nerve fibers thus causing nerve injury 
to the very distal processes of sensory fibers and leading to the development of 
neuropathic pain [58; 147].  Moreover, heightened excitability of peripheral 
nociceptors develops with the release of tumor-derived inflammatory products 
and the increase of tumor-induced acidosis [21; 120].  Morphological changes on 
the peripheral ends of nociceptors causes an increase in excitability called 
“peripheral sensitization.”   
 
11
   
Peripheral sensitization is characterized by the increased activation of C and Aδ 
nociceptors with mild noxious sensory stimuli being perceived as highly noxious, 
i.e. hyperalgesia, and normally non-noxious sensory stimuli being perceived as 
noxious stimuli, i.e. allodynia. Tumor-induced tissue injury produces retrograde 
signals to nociceptor neuron cell bodies in DRGs increasing the transcription of 
neuropeptides, growth factors, and signaling receptors such as transient receptor 
potential (TRP) channels in the nuclei of these injured sensory neurons. Taken 
together, these changes augment both central and peripheral sensitization, 
increasing spontaneous activity, and enhancing responsiveness to three modes 
of noxious stimulation: heat, cold, and mechanical stimuli 
 
TRP receptors and cancer pain 
TRP channels are predominantly expressed in C and Aδ nociceptors and 
transmit noxious thermal, mechanical and chemical stimuli. TRP channels are 
modulated by pro-inflammatory mediators, neuropeptides and cytokines.  As 
polymodal receptors that function at the peripheral nerve terminals and modulate 
synaptic transmission at the first sensory synapse between the DRG and dorsal 
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horn, these receptors are intrinsically involved in both peripheral and central 
sensitization of chronic pain states including bone cancer pain [34; 82; 108; 109].  
Known to be expressed in primary afferent nociceptors and the focus of current 
drug development efforts (reviewed in [17]) , this thesis will focus on three major 
TRP receptors: TRPV1, TRPA1, and TRPM8. 
 
TRPV1 - Molecular insights into the process of heat sensation came from the 
cloning and functional characterization of the vanilloid TRP (TRPV1) receptor that 
binds capsaicin, the main pungent ingredient in “hot” chili peppers [24].  TRPV1 
receptor is a non-selective Ca2+-permeable channel activated by capsaicin, 
vanilloid compounds, and multiple sensory stimuli including noxious heat (>42 
°C), acid, and mechanical stimulation [91] [150] [142].  In male rodent models of 
bone cancer pain, TRPV1 receptor expression and activation significantly 
increase in DRG neurons [70; 97; 153] and correlate with nocifensive behaviors 
mentioned above.  Conversely, in knock-out mice, TRPV1-/-, these behaviors 
have been significantly attenuated leading researchers to consider TRPV1 
receptor as a target for next generation analgesics  [82].  
13
   
 
Several clinically useful TRPV1 receptor antagonists and potent agonists have 
been synthesized and evaluated in animal models of cancer pain.  Specifically, 
antagonists SB-366791 (GlaxoSmithKline) and JNJ 17203212 (Johnson and 
Johnson) and the potent agonists, high-dose capsaicin and resiniferatoxin (RTX, 
obtained from the cactus, Euphorbia resinifera), block or ablate TRPV1 receptor-
expressing primary afferent fibers resulting in a loss of acute heat pain and 
mechanical sensitivity in animal models of bone cancer pain [95; 96; 108; 111; 
134].  These results suggest that the TRPV1 channel has a role in the integration 
of nociceptive signaling in chronic pain states, like bone cancer, and that the 
modification of TRPV1 receptor might be effective in attenuating tumor-induced 
pain which is typically difficult to treat. 
 
TRPA1 - TRP Ankyrin 1 (TRPA1) receptor is expressed in a subpopulation of 
nociceptors that also express TRPV1 receptors.  TRPA1 receptor is activated by 
a diverse assortment of pungent or irritating reactive chemical compounds 
including those found in mustard oil (allyl isothiocyanate) and cinnamon oil 
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(cinnamaldehyde), as well as, cold and mechanical force stimuli [6; 33; 76-78; 
129] eliciting a painful burning or prickling sensation. TRPA1 receptor has been 
shown to play a role in tumor growth [128].  In a rodent model of oral cancer, 
TRPA1 receptor expression increases in trigeminal nerves projecting to the tumor 
and it is suggested to play a role in tumor pain [149].   TRPA1 receptor’s role in 
bone cancer pain is yet to be delineated.  Research in animal models of other 
pain modalities, including inflammatory and neuropathic, show an important role 
of TRPA1 receptor in sensitization to both mechanical allodynia and cold 
hyperalgesia.   Antagonists to TRPA1 receptor have been shown to reduce 
mechanical allodynia in rodent models of inflammatory pain [69; 81; 102].  Sex 
differences in TRPA1 receptor activation have been demonstrated with respect to 
cold sensitivity with females requiring TRPA1 receptor to elicit an initial noxious 
cold response, whereas following prolonged exposure to cold, both males and 
females will respond. 
 
TRPM8 - TRP Melastatin 8 (TRPM8) receptor is expressed in a subset of both C 
and Aδ nociceptors on both the peripheral and central terminals [109].  TRPM8 
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receptor is also expressed in human prostate cancer cells and may be used as a 
diagnostic marker or a target for cancer therapy [151; 152] , but it’s role in bone 
cancer pain is still unknown.  In animal models of inflammatory and neuropathic 
pain, TRPM8 receptor is involved in cold hypersensitivity [7; 31; 42; 131]. 
Menthol, the major agonist of TRPM8, is a well-known analgesic, present in 
many over-the-counter drugs including cough drops and topical pain creams.  
Menthol reduces nocifensive behaviors in rodents with intradermal capsaicin 
injection and rodents with spinal nerve ligation, suggesting a role for TRPM8 
receptor activation to alleviate both acute and chronic pain conditions [108; 131].   
 
TRP receptors are important sensors of mechanical, chemical, and thermal 
stimuli.  During peripheral sensitization, DRG cell bodies receive nociceptor 
signals, which up-regulate the synthesis of TRP channels, thereby augmenting 
both central transmission and peripheral sensitization. Thus, nociception is 
influenced by changes in the number of TRP genes, their messenger RNAs, and 
protein products, along with their multimer organization.  Using the accumulated 
research on inflammatory and neuropathic pain, one could speculate that the use 
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of TRPV1 receptor and TRPA1 receptor antagonists with TRPM8 receptor 
agonist could be useful to treat certain modalities of pain. Although clinical trails 
using TRPV1 receptor antagonists for cancer pain are underway, the roles of 
TRPA1 receptor and TRPM8 receptor in cancer pain are still unknown.  
 
Overview of Thesis 
While conflicting views exist in the literature regarding sex differences in cancer 
pain, recent studies show that women are more likely to experience greater 
cancer pain than men.  Cycling sex steroid hormones are considered critical 
factors in sex-dependent differences in pain.  Whether estrogens and their 
receptors play role in sex differences linked to cancer pain has yet to be 
determined.  More specifically, a role for TRPV1 in bone cancer pain has been 
reported in males, but it is unknown what effect estradiol has on the in vivo 
function of TRPV1 in either sex.  Moreover, the role of TRPA1 and TRPM8 
receptors in bone cancer pain are unknown.   
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Using a well-established mouse model of bone cancer pain [141] we propose to: 
1. Determine whether sex differences exist in tumor-induced nociception; 2. 
Determine what effect estrogen has on this nociception; 3.  Delineate the tumor-
induced expression of TRP mRNA in lumbar DRG cell bodies.  Our overall 
hypothesis is that estrogen potentiates cancer pain by altering tumor-induced 
transcription of TRP receptors and their function.  If estradiol and its effect on 
TRP receptors contribute to sex differences in cancer pain, this will allow for 
selective and specific treatment of male and female pain patients based not only 




   
Chapter 2 
Effects of Chronic Estrogen on Bone Cancer Pain in a Rodent Model: Sex 
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 Introduction  
Sex plays a role in the vulnerability of humans to pain in experimentally-induced 
pain and in their sensitivity to analgesics [12; 14; 47; 55; 79; 94; 145].  The 
importance of sex differences in both acute and chronic pain conditions is 
demonstrated by the fact that women have a higher prevalence of several clinical 
and chronic pain conditions including fibromyalgia, arthritis, migraine, 
temporomandibular disorders, and irritable bowel syndrome [48; 49].  Some 
debate still exists in the literature regarding sex differences in patients with 
cancer pain. Early reports failed to find sex differences in cancer pain [28; 137] 
but more recent studies reveal that sex differences do exist [18; 71].  Women are 
more likely to experience enhanced cancer pain due to reduced treatment with 
analgesics [93] leading to a lower quality of life compared to their male 
counterparts [56].  Overall, basic and clinical studies are just beginning to 
delineate the full extent of sex differences in cancer pain.  
 
When examining sex differences, effects of gonadal hormone are a major focus 
of research [8; 57].  Fluctuations in female hormones over the menstrual cycle 
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correspond with changes in pain perception [39; 41; 49; 107; 112; 113].  
Estrogens are considered a critical factor in sex-dependent differences in pain, 
where they have a complex role in inflammatory processes and pain responses 
[2; 49; 115; 118], reviewed in [25].  The two classic estrogen receptors, ERα and 
ERβ, are widely expressed throughout the spinal cord and dorsal root ganglion of 
both males and females, with specific fluctuations depending on endocrine status 
[75; 99; 133; 139].  In contrast, GPR30, a G protein-coupled intracellular 
transmembrane estrogen receptor, does not change with hormonal rhythms [85].  
Progesterone and estrogen receptor activation increases neuropathic pain in a 
mouse model of spinal nerve injury [72], but they cause an antinociceptive effect 
in inflammatory and colorectal distention model of pain in rats [63; 74].   
 
Whether estrogens and their receptors play role in sex differences linked to 
cancer pain has yet to be determined.  In the present study, we utilized a mouse 
model of bone cancer [141] to delineate estrogen effects on cancer pain.  We 
hypothesize that estradiol will potentiate tumor-induced mechanical hyperalgesia 
21
   






Adult male and female C3H/He mice (8-10 wks of age) were obtained from the 
National Cancer Institute at NIH.  Mice were housed under a 12-h light/dark 
photoperiod with food and water available ad libitum.  All animal care was 
performed and supervised by the University of Minnesota Research Animal 
Resources.  All procedures were reviewed and approved by the University of 




To determine the effects of gonadal steroids, specifically 17β-estradiol (E), on 
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tumor nociception, a group of animals were gonadectomized (females: OVX, 
males: ORCH) with half receiving estrogen replacement (OVX+E, ORCH+E). On 
the day of surgery, animals were either gonadectomized, gonadectomized and 
given silastic-hormone implant, or subjected to sham surgery.  Surgical 
procedures were carried out under aseptic conditions according to “Principles of 
Laboratory Animal Care” (NIH publication, 8th Ed, revised 2011). Mice were 
placed in an enclosed chamber and anesthetized with isoflurane. When the 
animal were not responsive to paw pinch, it was removed from the chamber and 
fitted with a facemask that continuously delivered 1–2% isoflurane in an 
air/oxygen mixture throughout the surgery.  Ovariectomized females (OVX) had a 
5-mm dorsal incision made through the skin and two lateral incisions made 
through the left and right abdominal muscle wall.  Ligatures were placed around 
the oviduct and the ovary was removed above the ligation.  The muscle wall was 
closed with silk sutures and the skin closed with staples.  Orchectomized males 
(ORCH) had a 1-cm median incision through the scrotum and small incisions 
made through cremaster muscles to expose the testes.  Ligatures were placed 
around the vas deferens and the testes were removed above the point of ligation.  
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Skin and muscles were closed with silk sutures. Sham surgery animals received 
identical surgical procedures, but without the ligation and removal of the gonadal 
organs. 
 
For chronic estrogen replacement in OVX+E and ORCH+E animals, a 10-mm 
silastic implant  (i.d.: 1.57mm, o.d.: 3.18mm; Dow Corning, MI) containing 3 mg 
of crystalline 17β-estradiol (Sigma Chemical Co, St. Louis, MO) sealed at both 
ends with silicone medical adhesive was prepared and allowed to cure overnight.  
During gonadectomy surgery, the Silastic implant was placed subcutaneously 
(s.c.) through a small dorsal incision in the back.  Previous studies have 
determined that such implants produce high physiologic levels of serum estrogen 
in circulation [30; 106].  
 
Cell culture and implantation 
Cell culture and tumor cell implantation were performed as previously described 
(Cain et al. (Cain, 2001 #27). Briefly, NCTC clone 2472 connective tissue cells 
were obtained from American Type Cell Culture.  The cells were grown to 
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confluence in 75 cm2 flasks in NCTC 135 medium, pH 7.35, 10% horse serum, 
and passed one time weekly by a 1:4–6 split ratio.  The cells were then counted 
with a hemacytometer, pelleted, resuspended in PBS for implantation in a 
concentration of 2 x 105 cells/10 µl.  Mice were placed in an enclosed chamber 
and anesthetized with 1–2% isoflurane in an air/oxygen mixture. Cells were 
injected unilaterally into and around the calcaneus bone in a volume of 10 µl, 
whereupon the syringe was used both to bore through the calcaneus bone 
(proximal to distal) and inject the cells as the needle was withdrawn. This 
implantation protocol was derived from a femur skeletal metastasis model that 
has been used to study the cellular and biochemical mechanisms mediating bone 
destruction at the tumor site [29]. 
 
Measurement of hyperalgesia  
On the day of implantation, baseline values for mechanical and thermal 
sensitivity were determined for each animal randomly assigned to the cell-
implanted or saline-injected groups, prior to hindpaw implantation of fibrosarcoma 
cells.  Animals showing increased sensitivity to von Frey stimulation at baseline 
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were removed from this study.  A 3.4 milliNewton (mN) von Frey monofilament 
was used because the responses of tumor-bearing C3H/He mice to this 
monofilament are reproducible and sufficiently large to allow detection of dose-
dependent attenuation by analgesics or antagonists.  Because naïve mice 
typically do not respond to this size filament [19; 141], this hyperalgesic response 
can also be classified as allodynia.  Animals were placed on a wire mesh 
platform, covered with a hand-sized container, and allowed to acclimate to their 
surroundings for a minimum of 30 min before testing. The monofilament was 
applied 10 times (to the point of bending) on the plantar surface of each hindpaw.  
The number of vigorous responses to the monofilament were counted and 
expressed as a percentage of stimuli giving rise to a withdrawal response 
(percent response frequency).  Following the von Frey test, ankle widths were 
obtained to determine tumor size.  The tumor size was measured with a caliper 
and expressed in millimeters (mm).  Tumor growth was determined by 
subtracting the baseline measurement from the final growth measurement on 
post implantation day 21. There were no sex differences in tumor growth 
between male and female C3H mice injected with NCTC 2472 fibrosarcoma cells 
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into the hind paw tumor nor were there any differences in tumor growth among 
gonadal-hormone groups when compared to intact mice (Table 1).  Saline-
injected control animals did not show any increases in ankle width nor in 
mechanical allodynia (data not shown). 
 
Estrous cycle determination 
The stage of the estrous cycle for individual female mice was determined using 
vaginal cytology.  Samples were collected using swabs moistened with sterile 
saline; contents were smeared onto a slide and allowed to completely air-dry.  
Slides were placed in 95% EtOH for 5 min, and then stained in cresyl violet for 
20-30 min.  Slides were rinsed with water, allowed to air dry, and examined 
microscopically.  Based on the cytologic profile, mice were deemed to be in one 
of two hormones states: proestrus/estrus (high hormone milieu with a 
predominance of nucleated epithelial cells or cornified squamous cells) or 
diestrus (low hormone milieu with a predominance of leukocytes) [8; 22].  
 
Quantification of mRNA by real-time PCR 
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On post implantation day 21, dorsal root ganglia (DRG) L1–L5 were isolated from 
mice, placed in RNAlater (Qiagen) and stored at -80°C. Total RNA was isolated 
from DRG samples using RNeasy Lipid Tissue Mini Kits (Qiagen). RNA was 
reverse transcribed into cDNA using QuantiTect RT-PCR kits (Qiagen) as per the 
manufacturer’s instructions. Real-time PCR experiments were performed with 
Perfecta SYBR Green Master Mix (Quanta) using Stratagene's Mx3000P Real-
Time PCR Systems (Agilent Technologies).  Each cDNA sample was run in 
triplicate for murine ERα, ERβ, GPR30, and PGR and reference gene (β-actin).  
Primers were developed using NCBI Primer-BLAST 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) and synthesized at the 
BioMedical Genomics Center at the University of Minnesota. Primer pair 
sequences were as follows: ERα receptor (GenBank Accession number 
NM_001001445.1) forward primer 5’- TGATGAAAGGCGGCATACGG -3’ and 
reverse primer 5’- TCAAGGACAAGGCAGGGCTA -3’; ERβ (NM_177781.4) 
forward primer 5’- GCTGGGCCAAGAAAATCCCT -3’ and reverse primer 5’- 
TGAGGACCTGTCCAGAACGA -3’; GPR30 (NM_ 134252.3) FORWARD 
PRIMER 5’- CTTCATCATGCCCTTCGCCA- 3’ and reverse primer 5’- 
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GCGAAGATCATCCTCAGGGC -3’; β-actin (NM_007393.3) forward primer 5’- 
AGGAGTACGATGAGTCCGGC -3’ and reverse primer 5’- 
GCAGCTCAGTAACAGTCCGC -3’.  PGR (NM_ 134252.3) FORWARD PRIMER 
5’- CGTGTCGTCTGTAGTCTCGC- 3’ and reverse primer 5’- 
ACTGCTGGTCCCCTGTCTTT -3’; β-actin (NM_007393.3) forward primer 5’- 
AGGAGTACGATGAGTCCGGC -3’ and reverse primer 5’- 
GCAGCTCAGTAACAGTCCGC -3’. The ratio of fold change in expression of the 
mRNA of interest for each sample was calculated by normalization of cycle 
threshold (Ct) values to β-actin.  Using the equation derived by Pfaffl [103] to 
correct for potential differences in PCR primer efficiencies between the target and 
reference genes, Ct values for tumor-bearing animals were normalized to the 
averaged Ct values calculated for saline-injected counterparts; Ct values for 
saline-injected animals were normalized to the averaged Ct values calculated 
from their own group.  The fold change was then derived from the differences 




   
Results were analyzed with JMP software (v.9.0.0 Copyright © 2010 SAS 
Institute Inc., Cary, NC, USA). Values were represented as mean ± SEM 
(standard error of the mean).  Between group comparison of the mean frequency 
of withdrawal responses to mechanical stimuli were analyzed by one-way 
ANOVA with a Tukey-Kramer HSD.  Between group comparison of the relative 
mRNA expression were analyzed by one-way ANOVA with a Tukey-Kramer 
HSD.  Bivariate analysis was used to evaluate correlational data between relative 
mRNA expression and hyperalgesia responses.  A value of p < 0.05 was 
considered statistically significant. 
 
Results 
In the present study, we used a well-characterized mouse model of bone cancer 
pain [141] to determine to what extent gonadal hormones contribute to tumor-
induced nociception.  At post implantation day (PID) 21, tumor-induced 
mechanical allodynia was assessed by the animals’ responses to von Frey fibers 
(Fig 1).  There were no significant differences between intact males and females 
(79.3±3.3% and 72.0±2.8% respectively, p=0.10).  However, females in the 
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proestrus/estrus phase of the estrus cycle had greater tumor-induced mechanical 
allodynia (76.4±2.9%) than females in diestrus (61.7±4.0%, p=0.01).   To 
evaluate in more detail the effect of female sex hormones on tumor-induced 
nociception, we gonadectomized females (OVX) and replaced 17β-estradiol 
(OVX+E).  Tumor-induced mechanical allodynia in OVX females (67.5±7.5%) 
was similar to that observed in diestrus females (p=0.98).  Conversely, OVX+E 
females (90.0±4.1%) were more sensitive than intact females in the 
proestrus/estrus phase (p=0.03).  These results indicate that 17β-estradiol 
contributes to enhanced mechanical allodynia in females.    
 
Previous research has shown that circulating sex steroid hormones in males are 
associated with reduced nociception [54; 126], thus we examined the effect of 
gonadectomy on male tumor-induced nociception (ORCH) and the effect of 17β-
estradiol replacement (ORCH+E).  ORCH males had greater tumor-induced 
allodynia (96.0±2.4%) than intact male counterparts (p=0.005).  Conversely, 
ORCH+E males had reduced mechanical allodynia (64.0%±5.1%, p<0.0001) 
similar to OVX and diestrus females (p=0.89 and p=0.72, respectively).  This 
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indicates an anti-nociceptive rather than a pro-nociceptive effect of estrogen in 
males.  
 
To examine tumor-induced changes in estrogen and progesterone receptors, the 
fold change of receptor mRNA from lumbar DRG cell bodies was quantified at 
PID 21 (Fig 2).  ERα mRNA expression differed significantly across experimental 
groups (F(5, 47)=4.52, p=0.00) and a Tukey-Kramer HSD post hoc test showed 
that tumor-bearing OVX females had a greater relative fold expression of ERα 
(3.09±0.48) compared to intact tumor-bearing males (-1.01±0.37, p=0.01) and 
ORCH males (-1.41±1.02, p=0.01, Fig 2A). There were no differences in ERβ 
mRNA expression across experimental groups (F(5, 47)=173, p=0.15, Fig 2B).  
However, there were differences in the relative expression of GPR30 (F(5, 
47)=4.13, p=0.009, Fig 2C) with tumor-bearing OVX females having a greater fold 
expression of GPR30 (3.49±1.49) compared to tumor-bearing intact males (-
1.11±0.76, p=0.03) and intact females (-1.32±0.51, p=0.006).  When the phase of 
estrous cycle was factored into the analysis, proestrus/estrus females (-
1.96±0.41) have a greater fold decrease in GPR30 mRNA compared to OVX 
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(3.49±1.49), diestrus females (1.54±0.82), and ORCH males (1.71±0.26; 
p=0.0001, p=0.04, & p=0.02, respectively).  PGR mRNA relative expression 
differed across groups (F(5, 47)=13.04, p=0.00, Fig 2D) and was greatest in tumor-
bearing females (8.21±2.43, p<0.0001) compared to all other groups.  When the 
phase of estrous cycle was factored into the analysis of PGR mRNA expression, 
tumor-bearing proestrus/estrus females (10.15±2.68) had the highest fold 
expression compared to all other groups (p<0.0001).  Whereas, diestrus females 
(5.19±0.04) had a higher relative expression compared to intact males (-
2.54±0.96, p=0.001).  These results suggest that estrogens effect the tumor-
induced relative expression of estrogen and progesterone receptor mRNA. 
 
To examine the full spectrum of von Frey fiber responses in treatment groups 
relative to their expression of mRNA for hormone receptors, we utilized statistical 
prediction to correlate tumor-induced mechanical allodynia and the tumor-
induced changes in mRNA expression.  Overall, ERα negatively correlated with 
tumor-induced mechanical allodynia (R=-0.331, p=0.023) with intact tumor-
bearing females having the greatest negative correlation (R=-0.553, p=0.012, Fig 
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3A).  Similarly, intact female GPR30 expression was negatively correlated with 
mechanical allodynia (R=-0.566, p=0.0009, Fig 3B). Conversely, there were no 
significant correlations for ERα or GPR30 and mechanical allodynia in intact 
males, gonadectomized, and gonadectomized with 17β-estradiol replacement 
animals (data not shown).  Moreover, ERβ and PGR had no predictable effect 
(data not shown).   Taken together, these relationships suggest a link between 
tumor-induced mechanical allodynia and the natural changes in sensitivity of 
DRG cells to estrogen.  
 
Discussion  
Based on evidence in the literature that estrogen increases nociception in animal 
models of pain [118], as previously reviewed [25], we hypothesized that tumor-
induced bone cancer pain will increase in the presence of estrogen and, 
conversely, decrease when estrogen is removed.  Furthermore, based on 
evidence that sex steroid hormones in males reduce nociception in models of 
pain [72], we hypothesized that both male and female nociception will vary based 
on the presence or absence of sex steroid hormones. 
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Our results provide several important and novel findings related to tumor-induced 
nociception and the effects of sex steroid hormones.  First, we demonstrate that 
the stage of estrous cycle affects tumor-induced mechanical hyperalgesia with 
females in diestrus exhibiting reduced mechanical hyperalgesia compared to 
females in proestrus/estrus.  To control cyclical effects of female sex steroid 
hormones, we removed the ovaries (OVX) and replaced 17β-estradiol (OVX+E).  
OVX animals have mechanical allodynia similar to diestrus cycling females.  
Mechanical allodynia is greater in OVX+E and proestrus/estrus females.  These 
results reveal estrous cycle effects and indicate that female sex steroid 
hormones, specifically estradiol, enhance tumor-induced nociception.   
 
In other models of pain, sex steroid hormones in males reduce nociception [54; 
126].  Thus, we examined the effect of tumor-induced nociception on 
gonadectomized males (ORCH) and in males with 17β-estradiol replacement 
(ORCH+E).  Consistent with previous findings, ORCH males have greater tumor-
induced mechanical allodynia compared to either intact or estrogen replaced 
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counterparts.  A novel finding in our work is that estrogen replacement 
(ORCH+E) reduced mechanical allodynia and was similar to females with 
reduced sex steroid hormones (diestrus/OVX).  This suggests an opposite role 
for estrogen in males and females with tumor-induced nociception.  Furthermore, 
these findings suggest that male’s circulating hormones are necessary for 
reduced tumor-induced nociception and that estrogen plays a role in this 
phenomenon.   
 
Previous research has shown that an increase in expression and activation of 
estrogen receptors will enhance nociception in rodent models of pain [35; 45; 64; 
75; 83; 85; 125], while other research finds their expression and activation to be 
anti-nociceptive [23; 35; 86].  To delineate tumor-induced changes in estrogen 
and progesterone receptors, we examined ERα, ERβ, GPR30, and PGR mRNA 
expression in lumbar DRG cell bodies.  The removal of circulating hormones 
increased ERα and GPR30 expression in OVX females.  While correlational 
analysis indicated intact female mechanical allodynia is negatively correlated with 
both ERα and GPR30 expression.  Thus, the greater the ERα and GPR30 
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expression, the less sensitive tumor-bearing females are to von Frey stimulation.   
Agonists for ERα and GPR30 have been shown to reduce inflammatory pain in 
OVX and diestrus phase female rats [86].  Moreover, 17β-estradiol can act 
directly on DRG cell bodies to reduce capsaicin induced TRPV1 receptor 
activation [148] and ERα knock-out mice are more sensitive to a formalin 
nociceptive response [35].  Together this work indicates an anti-nociceptive effect 
of ERα.   Based on variations in estrogen receptor transcription over the estrous 
cycle, increases in mechanical nociceptive sensitivity during proestrus/estrus 
correspond with decreases in estrogen receptor synthesis.  Conversely, 
decreased nociceptive sensitivity during diestrus corresponds with greater 
estrogen receptor expression.  Thus, these relationships would suggest that 
estrogen treatment is antinociceptive during diestrus rather than during 
proestrus/estrus.  
 
Progesterone increases neuropathic pain in male rodents [72], while other work 
has demonstrated that the combination of progesterone and estradiol produces 
an antinociceptive in female rodents [63; 74].  These contrasting findings could 
37
   
be due to sex differences in the expression of PGRs during inflammatory and 
neuropathic pain states.  Our work illustrates sex differences in tumor-induced 
PGR mRNA expression.  Tumor-bearing females have an 8-fold increase in PGR 
mRNA, whereas, males have a -2.5 fold decrease.  Progesterone 
supplementation reduces the antinociceptive effect of morphine in intact female 
rats [144].  Thus, enhanced mechanical allodynia and enhanced expression of 
the progesterone receptor during the proestrus/estrus of the estrous cycle would 
suggest that either a reduction in progesterone concentrations and/or 
supplementation a progesterone antagonist could be antinociceptive in tumor-
bearing females.  
 
Our findings in a mouse model of bone cancer indicate estrogens increase pain 
in females and reduce pain in males.  Moreover, removal of estrogens effects 
tumor-induced changes of estrogen receptor mRNA in females, while increased 
female sex hormones increases progesterone receptor mRNA.  Taken together, 
changes in both estrogen concentration and estrogen receptor effect tumor-
induced nociception in females.  In light of this, intact cycling females and the 
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examination of specific sex-steroid fluctuations is necessary to evaluate the 
development, maintenance, and possible analgesic paradigms on pain modalities 








OVX 4.43 0.83 6.8 - 2.9 4± 
OVX E 5.10 0.39 5.9 - 4.3 4± 
ORCH 4.10 0.94 6.7 - 2.0 5± 
ORCH E 5.5 - 2.2 53.74 0.58± 
Females 4.22 0.48 7.0 - 1.0 20± 
Males 4.11 0.41 6.9 - 1.7 15± 
TABLE: ANKLE TUMOR SIZE
Table: Ankle tumor size
Summary of average tumor growth as measured on PID 21. 
The tumor size was measured with a caliper and expressed 
in millimeters (mm).  Tumor growth was determined by 
subtracting the baseline measurement from the ???al 
growth measurement on post implantation day 21.  
Data is shown as group means ± SEM.  Range of ankle 
width and sample size of all experimental groups are also 
shown.
40


























Figure 1:  Von Frey mechanical allodynia
Estrogen a???cts tumor-induced mechanical allodynia in both 
males and females.  Von Frey ???er testing of the hind paw 
assessed mechanical allodynia. Intact males were statistically 
similar to intact females. Data are presented as group percent 
response means, % ± SEM.  *P<0.05
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Figure 2: Relative mRNA expression
Sex and hormones status in???ence tumor-induced changes in lumbar dorsal root 
ganglia (DRG) ER?????(A), GPR30 (C), and PGR (D), but no ER???????mRNA expression. 
Data are shown as mean fold change ± SEM. *P<0.05; #P<0.05 compared to intact 
males, OVX, OVX+E, ORCH, and ORCH+E.
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FIGURE 3:  Correlational analysis of mechanical allodynia and 
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Figure 3:  
Correlational analysis of mechanical allodynia and relative mRNA expression
Bivariate correlational analyses were used to determine the statistical 
signi???ance of the relationship between tumor-induced mechanical allodynia 
and ER?????(A) and GPR30 (B) mRNA expression in intact males and intact females.  
*P<0.05
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Chapter 3 
Estrogen effects on Bone Cancer Pain in a Rodent Model: Sex Differences, 




J.L. Triemstra, A. A. Larson, and A. J. Beitz 
Department of Veterinary & Biomedical Science, University of Minnesota  
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Introduction 
Sex differences in the degree of pain experienced in a variety of human health 
conditions and some diseases are well documented in both clinical and 
experimental research [11; 47; 48; 57; 84].  Research is just beginning to 
delineate sex differences in cancer pain.  Clinical reports indicate that women 
cancer patients have reduced quality of life due to reduced prescription of 
analgesics and, as a consequence, enhanced cancer pain [56; 93].   
 
Malignant bone tumors occur not only in patients with primary bone cancer, but 
also as distant metastases from non-bone primary tumors, such as breast, 
prostate, and lung cancer.  Tumor growth invades soft and boney tissue 
changing the chemical milieu, provoking inflammatory cell responses, and 
distorting a normally innocuous mechanical response.  These changes in milieu 
sensitize nociceptors to both noxious and innocuous input [60; 61; 146].  During 
peripheral sensitization, dorsal root ganglion (DRG) cell bodies receive 
nociceptive signals which up-regulate the synthesis of transient receptor potential 
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(TRP) ion channels, thereby augmenting both central and peripheral sensitization 
(reviewed in [130])  
 
An array of TRP ion channels are known to be involved with tumor-growth and 
cancer-induced nociception [108; 109].  Specifically, ankyrin-1 (TRPA1) is 
normally activated by a diverse assortment of irritating chemical compounds 
including those found in mustard oil (allyl isothiocyanate).  TRPA1 is also 
activated by mechanical force stimuli [6; 76] as well as noxious cold [33; 67; 77; 
129].  TRPA1 antagonists reduce pain responses in male rodents with tumor-
tissue associated inflammation [135].  Relevant to the current study, TRPA1 
expression increases in trigeminal nerves projecting to oral cancer in female mice 
[149].  
 
Another TRP receptor, melastatin-8 (TRPM8) is involved in both cooling-
mediated analgesia and cold hypersensitivity after injury in rodent models of pain 
[7; 31; 42; 131].  Menthol, a TRPM8 agonist, decreases nociception in both 
human patients and animal models of inflammatory and neuropathic pain [52; 66; 
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98; 136].   TRPM8 is expressed in human prostate cancer cells and may be used 
as a diagnostic marker or a target for cancer therapy [152].   
 
Based on the role of TRP receptors in pain and the greater sensitivity to cancer 
pain in females than males, estrogen may influence TRP receptor activity.  
Whether sex differences in cancer pain are due to the effects of sex hormones on 
TRPA1 and TRPM8 receptors has yet to be delineated.  In the present study, we 
hypothesized that sex steroid hormones alter tumor-induced transcription of TRP 
receptors in DRG neurons as well as influence the response to TRPM8 sites to 
activation by menthol.  Utilizing a mouse model of bone cancer [141], we 
compared intact, gonadectomized, and estradiol-replaced males and females to 
delineate gonadal hormones effect on tumor-induced TRPA1 and TRPM8 
receptor expression and nociception.  We also examined the antinociceptive 
effects of a topical application of menthol on tumor-induced mechanical allodynia 
and thermal hyperalgesia to determine if sex hormones, specifically estradiol, 
affects cooling-mediated analgesia.   
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Adult male and female C3H/He mice (8-10wks of age) were obtained from 
National Cancer Institute.  Mice were housed under a 12 hour light/dark 
photoperiod with food and water available ad libitum.  All animal care was 
performed and supervised by the University of Minnesota Research Animal 
Resources.  All procedures were reviewed and approved by the University of 
Minnesota Institutional Animal Care and Use Committee. 
 
Surgery 
To determine the effects of gonadal steroids, specifically estradiol, on 
nociception, animals were gonadectomized (females: OVX, males: ORCH) with 
half receiving estrogen replacement (OVX+E, ORCH+E).  Surgical procedures 
were carried out under aseptic conditions according to “Principles of Laboratory 
Animal Care” (NIH publication, 8th Ed, revised 2011). Mice were placed in an 
enclosed chamber and anesthetized with isoflurane in preparation for 
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gonadectomy. When the animals did not respond to paw pinch, it was removed 
from the chamber and fitted with a facemask that continuously delivered 1–2% 
isoflurane in an air/oxygen mixture throughout the surgery.  On the day of 
surgery, animals were either gonadectomized, gonadectomized and given 
silastic-hormone implant, or subjected to sham surgery.  Briefly, ovariectomized 
females (OVX) had a 5 mm dorsal incision made through the skin and two lateral 
incisions made through the left and right abdominal muscle wall.  Ligatures were 
placed around the oviduct and the ovary was removed above the ligation.  The 
muscle wall was closed with silk sutures and the skin closed with staples.   
 
Orchectomized males (ORCH) had a 1 cm median incision through the scrotum 
and small incisions made through cremaster muscles to expose the testes.  
Ligatures were placed around the vas deferens and the testes were removed 
above the point of ligation.  Skin and muscles were closed with silk sutures. 
Sham surgery animals received identical surgical procedures but without the 
ligation and removal of the gonadal organs. 
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For chronic estrogen replacement in OVX+E and ORCH+E animals, a Silastic-
implant  (i.d.: 1.57mm, o.d.: 3.18mm; Dow Corning, MI) containing 3 mg of 
crystalline 17β-estradiol (Sigma Chemical Co, St. Louis, MO) sealed at both ends 
with silicone medical adhesive was prepared and allowed to cure over night.  
During gonadectomy surgery, the Silastic implant was placed subcutaneously 
(s.c.) through a small dorsal incision in the back.  Previous studies have 
determined that such implants produce high physiologic levels of serum estrogen 
in the circulation [30; 106].   
 
Cell culture and implantation 
Cell culture and implantation were performed per Cain et al. [21]. Briefly, mice 
were placed in an enclosed chamber and anesthetized in preparation for cell 
implantation. When the animal did not respond to paw pinch, it was removed 
from the chamber and fitted with a facemask that continuously delivered 1–2% 
isoflurane in an air/oxygen mixture throughout the implantation. NCTC clone 
2472 connective tissue cells were obtained from American Type Cell Culture.  
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The cells were grown to confluence in 75 cm2 flasks in NCTC 135 medium, pH 
7.35, 10% horse serum, and passed one time weekly by a 1:4–6 split ratio.  The 
cells were then counted with a hemacytometer, pelleted, resuspended in PBS for 
implantation in a concentration of 2 x 105 cells/10µl.  Cells were injected 
unilaterally into and around the calcaneus bone in a volume of 10µl, whereupon 
the syringe was used both to bore through the calcaneus bone (proximal to 
distal) and inject the cells as the needle was withdrawn. This implantation 
protocol was derived from a femur skeletal metastasis model that has been used 
to study the cellular and biochemical mechanisms mediating bone destruction at 
the tumor site [29]. 
 
Measurement of hyperalgesia  
On the day of implantation, baseline values for mechanical and thermal 
sensitivity were determined for each animal randomly assigned to the cell-
implanted or saline groups, prior to hindpaw implantation of fibrosarcoma cells.  A 
3.4 milliNewton (mN) von Frey monofilament was used because the responses of 
tumor-bearing C3H/He mice to this monofilament are reproducible and 
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sufficiently large to allow detection of dose-dependent attenuation by analgesics 
or antagonists [21; 141].  Testing was repeated throughout the time course of 
each study.  Briefly, animals were placed on a wire mesh platform, covered with 
a hand-sized container, and allowed to acclimate to their surroundings for a 
minimum of 30 min before testing. The monofilament was applied 10 times to the 
point of bending on the plantar surface of each hindpaw.  The number of vigorous 
responses to the monofilament were counted and expressed as a percentage of 
stimuli giving rise to a withdrawal response (percent response frequency).  
 
Cold plate response latencies were obtained from mice placed on an aluminum 
plate cooled with ice (1±2°C).  Latency to hind paw withdrawal/lift from the 
surface not related to general movements was determined as the end point.  
Mice were tested for a maximum of 30 s for each session. Data was recorded as 
threshold in s.  There was at least a 30-min rest between mechanical and 
thermal testing.  In a separate group of both fibrosarcoma-injected and naïve 
C3H mice, we applied menthol (10%, Biofreeze, Akron, OH) to the hindpaw 
plantar surface using cotton swab soaked with 500µl of solution.  Between 30-60 
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min following application, the latency of response to a von Frey fiber was 
obtained; 30 min after which, cold plate latencies were measured.  
 
Following the cold plate test, ankle widths were obtained to determine tumor size.  
The tumor size was measured with a caliper and expressed in millimeters (mm).  
Tumor growth was determined by subtracting the baseline measurement from the 
measurement on that post implantation day.   While tumor growth was evident, 
there were no sex differences in tumor growth between male and female C3H 
mice injected with NCTC 2472 fibrosarcoma cells into the hind paw tumor nor 
were there any differences in tumor growth among gonadal-hormone groups 
when compared to intact mice (data not shown).  In saline-injected control 
animals the ankle width and mechanical nociceptive sensitivity did not change 
over the course of the experiments (data not shown). 
 
Estrous cycle determination 
Stage of the estrous cycle for individual female mice was determined using 
vaginal cytology.  Samples were collected using swabs moistened with sterile 
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saline; contents were smeared onto a slide and allowed to completely air-dry.  
Slides were placed in 95% EtOH for 5 min, and then stained in cresyl violet for 
20-30 min.  Slides were rinsed with water, allowed to air dry, and examined 
microscopically.  Based on the cytologic profile, mice were deemed to be in one 
of two hormones states: proestrus/estrus (high hormone milieu with a 
predominance of nucleated epithelial cells or cornified squamous cells) or 
diestrus (low hormone milieu with a predominance of leukocytes) [8; 22].   
 
Quantification of mRNA by real-time PCR 
Dorsal root ganglia L1–L5 were isolated from mice, placed in RNAlater (Qiagen, 
Valencia, CA) and stored at -80°C. Total RNA was isolated from DRG samples 
using RNeasy Lipid Tissue Mini Kits (Qiagen, Valencia, CA). RNA was reverse 
transcribed into cDNA using QuantiTect RT-PCR kits (Qiagen, Valencia, CA) as 
per the manufacturer’s instructions. Real-time PCR studies were performed with 
Perfecta SYBR Green Master Mix (Quanta, Gaithersburg, MD) using 
Stratagene's Mx3000P Real-Time PCR Systems (Agilent Technologies, Santa 
Clara, California). 
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Each cDNA sample was run in triplicate for the murine TRPA1 and TRPM8 
receptor and the reference gene (β-actin).  Primers were developed using the 
NCBI Primer-BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) and 
synthesized at the BioMedical Genomics Center at the University of Minnesota. 
Primer pair sequences were as follows: TRPA1 (NM_177781.4) forward primer 
5’- CCTCCCCGAGTGCATGAAAG -3’ and reverse primer 5’- 
CCACATCCTGGGTAGGTGCT -3’; TRPM8 (NM_ 134252.3) FORWARD 
PRIMER 5’- TTTACCACGCACTGTGTCCC- 3’ and reverse primer 5’- 
CGCATAGGAAATGGCGTTGC -3’; β-actin (NM_007393.3) forward primer 5’- 
AGGAGTACGATGAGTCCGGC -3’ and reverse primer 5’- 
GCAGCTCAGTAACAGTCCGC -3’.  The ratio of fold change in expression of the 
mRNA of interest for each sample was calculated by normalization of cycle 
threshold (Ct) values to β-actin.  Using the equation derived by Pfaffl [103] to 
correct for potential differences in PCR primer efficiencies between the target and 
reference genes, Ct values for tumor-bearing animals were normalized to the 
averaged Ct values calculated for saline-injected counterparts; Ct values for 
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saline-injected animals were normalized to the averaged Ct values calculated 
from their own group.  The fold change was then derived from the differences 




Results were analyzed with JMP software (v.9.0.0 Copyright © 2010 SAS 
Institute Inc., Cary, NC, USA). Values were represented as mean ± SEM 
(standard error of the mean).  The mean frequency of withdrawal responses to 
mechanical stimuli and mean latency to respond for thermal stimuli were 
analyzed by repeated-measures ANOVA with Tukey-Kramer HSD or unpaired 
Student’s t-test post hoc comparison.  Between group comparison of the relative 
mRNA expression were analyzed by one-way ANOVA with a Tukey-Kramer 




   
Mechanical allodynia was similar in both males and females (F(1,28)=0.6317, 
p=0.433) as responses to the von Frey fiber increased similarly over time 
(F(5,24)=4.3436, p=0.0059, Fig 1A).  There was also a significant difference in 
tumor-induced mechanical allodynia between females in diestrus and females in 
proestrus/estrus (F(1,13)=9.9933, p=0.0075, Fig 1B).  These results suggest that 
circulating female sex steroid hormones associated with the estrous cycle 
enhance tumor-induced mechanical allodynia.   
 
To examine estradiol’s effect on tumor-induced nociception, we gonadectomized 
females (OVX) in one group of mice and replaced 17β-estradiol (OVX+E) in 
another. There was a pronociceptive effect of estradiol replacement 
(F(1,6)=6.1413, p=0.0479) as tumor-induced mechanical allodynia was enhanced 
in OVX+E females compared to OVX females (Fig 1C).  Because previous 
research has shown that circulating sex steroid hormones in males reduce 
nociception [54; 127], we examined the effect of gonadectomy (ORCH) and 17β-
estradiol replacement (ORCH+E) on tumor-induced nociception in males.  There 
was an antinociceptive effect of estradiol replacement on mechanical allodynia 
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(F(1,8)=32.3025, p=0.0005) as ORCH+E males had reduced mechanical allodynia 
(Fig. 1D).  These results indicate that while there is no difference between intact 
males and females in sensitivity to mechanical pain, estrogen increases 
nociception in females but decreases it in males.   
 
When examining tumor-induced thermal hyperalgesia in intact males and 
females, there was a significant effect of sex (F(1,28)=7.9259, p=0.0088) that 
persisted over time (F(5,24)=2.8320, p=0.0379).   Females had a reduced threshold 
compared to males (Fig. 2A).  There was no difference between tumor-induced 
thermal hyperalgesia in mice during proestrus/estrus compared to that during 
diestrus (F(1,13)=3.2325, p=0.0954) except on PID 11 (p=0.0465, Fig 2B).  The 
removal of circulating female sex hormones (OVX) and replacement of 17β-
estradiol (OVX+E) had a significant effect over time (F(5,30)=3.3696, p=0.0156, Fig 
2C).  Between groups, there was no effect (F(1,6)=1.3845, p=0.2839), except at 
PID 21 when OVX+E females were more sensitive than OVX females (p=0.0492).   
The removal of circulating male sex hormones (ORCH) and replacement of 17β-
estradiol (ORCH+E) each had a robust effect over time (F(5,40)=5.2056, p=0.0009), 
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but there was no significant difference between these groups at any time tested 
(F(1,8)=0.2666, p=0.6196, Fig 2D).  Together, these results suggest females are 
more sensitive than males to tumor-induced thermal hyperalgesia and although 
male sex steroids had a protective effect in males, estrogen has little or no effect 
on thermal hyperalgesia in either sex. 
 
Because TRPA1 expression increases in trigeminal nerves of mice with oral 
cancer [149], we examined the tumor-induced expression of TRPA1 in lumbar 
DRGs.  TRPA1 mRNA expression differed significantly across experimental 
groups (F(5, 47)=14.6699, p<0.0001) and post hoc tests showed that TRPA1 
mRNA expression was less in tumor-bearing intact females than intact males 
(Fig 3A).  There were no differences between diestrus and proestrus/estrus (data 
not shown).  TRPM8 mRNA expression differed across experimental groups 
(F(5,47)=2.5501, p=0.0402) such that intact males had less TRPM8 mRNA 
expression compared to intact females (Fig 3B).  There were no differences 
between the phases of the estrous cycle (data not shown).  These results 
indicate that there were sex differences in the tumor-induced expression of both 
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TRPA1 and TRPM8, but neither alteration of sex steroid hormones nor the 
replacement of 17β-estradiol had any effect on this expression.  
 
To examine the anti-hyperalgesia effect of menthol in tumor-induced nociception, 
we applied 10% menthol to the plantar surface of the tumor foot. The change in 
von Frey responses (Fig 4A) and cold plate threshold (Fig 4B) are shown as 
group mean (±SEM).  In all tumor-bearing animals, menthol reduced von Frey 
fiber responses.  The hormone status of the animal is a factor in menthol-
induced mechanical antinociception (F(5,31)=7.069, p=0.0002) as OVX females 
and ORCH+E males had diminished antinociceptive effects compared to intact 
males, intact females, OVX+E, and ORCH (Fig 4A).  In all tumor-bearing animals, 
menthol reduced von Frey fiber responses.  The hormone status of the animal is 
a factor in menthol-induced thermal antinociception (F(5,31)=3.486, p=0.0129) as 
OVX females had diminished antinociceptive effects compared to intact females, 
OVX+E, ORCH and ORCH+E (Fig 4A).  The antinociceptive effect of menthol in 
OVX females did not differ from intact males.  For both von Frey and cold plate 
assessments, there were no differences between the phases of the estrous 
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cycle on menthol antinociception (data not shown).  Menthol had no effect in 
naïve, non-tumor-bearing, animals (data not shown).  These results suggest that 
female sex steroid hormones are necessary for menthol to have an 
antinociceptive effect in tumor-bearing female mice.  
 
Discussion 
Our animal model of cancer pain increased von Frey fiber responses and cold 
plate latencies of response, indicating increased sensitivity to both tactile and 
thermal (cold) pain in both male and female mice.  Females were more sensitive 
to the cold plate than males, but both were equally sensitive to the von Frey fiber.  
In spite of the lack of difference between males and females in their degree of 
mechanical allodynia, estrogen, either released endogenously during the estrus 
cycle or delivered after gonadectomy, increased von Frey fiber responses in 
females but decreased them in males.  In contrast, cold-plate hyperalgesia was 
relatively insensitive to changes in estrogen, as indicated by the failure of the 
estrus cycle or addition of estrogen to gonadectomized mice to alter cold 
sensitivity.  The greater sensitivity of females to cold is consistent with the fact 
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that females and female sex steroid hormones sensitize mice to cold [114; 119] 
and cold hyperalgesia [76].   
 
Males and females also differed in their expression of cancer-induced changes in 
TRPA1 and TRPM8 expression, where intact males expressed more TRPA1 and 
intact females express more TRPM8.  TRPA1 remained unchanged in males with 
hormonal manipulation while the decrease in TRPA1 in females was reversed by 
gonadectomy and not influenced further by estrogen. TRPA1 is considered a 
thermo-TRP that is gated by noxious cold and mechanical force [3; 76; 78].  
TRPA1 has been implicated in mechanical allodynia in male rodent models of 
inflammatory pain [69; 102] [81] and cold plate and tail-flick experiments reveal 
TRPA1-dependent, cold-induced nociceptor behavior in mice [67].  The 
difference in TRPA1 mRNA expression between intact and gonadectomized 
females could be due to the influence of progesterone or other sex steroid 
hormones (e.g. leuteinizing hormone, follicle stimulating hormone).  Moreover, 
we show that estradiol replacement does not affect the expression of TRPA1 
suggesting other sex steroid hormones may influence TRPA1 mRNA expression.  
   
Additionally, this phenomenon of less TRPA1 mRNA expression, but greater cold 
sensitivity in females compared to males could be due to a down-regulation of 
TRPA1 receptors in response to their enhanced activity.  As mechanical allodynia 
and cold hypersensitivity increase, TRPA1 mRNA is decreased.   
 
Tumor-induced TRPM8 mRNA expression was increased in females but was not 
influenced by hormonal manipulation.  In males, the decrease in tumor-induced 
expression of TRPM8 was reversed following gonadectomy.  Given that 
androgens affect the expression of TRPM8 mRNA in prostate tumor cells [5], 
androgens may similarly affect their expression in DRG neurons of tumor-bearing 
mice.  The dissimilar changes of TRPM8 mRNA expression between intact males 
and females are consistent with the sensitivity of tumor-bearing mice to cold.   
Tumor-induced cold sensitivity differed by sex but was relatively insensitive to 
hormonal manipulation.  This is comparable to rodent models of inflammation or 
nerve injury, where increased TRPM8-dependent hypersensitivity to cold 
develops together with increased TRPM8 expression and/or TRPM8 
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responsiveness in nociceptors  [31; 110].   Taken together, this would suggest 
that testosterone attenuates cold sensitivity. 
 
Menthol, a TRPM8 agonist, is a natural compound of plant origin that is anti-
hyperalgesic at low concentrations [38; 66; 136; 143].   In our hands, activation of 
TRPM8 using menthol produced an antinociceptive effect, consistent with that 
indicated throughout the literature.  To our knowledge, the present study is the 
first to show an antinociceptive effect of topical menthol on tumor-induced pain.  
The efficacy of menthol appears to be sex dependent. In females, the effects of 
menthol on cold and mechanical pain were decreased by OVX but restored by 
estrogen.  In contrast, menthol-induced cold antinociception was not influenced 
greatly by gonadal hormones in males, yet mechanical antinociception was 
attenuated by addition of estrogen in ORCH males.  Taken together, our results 
suggest menthol is a potential analgesic for tumor-induced nociception, but the 
antinociceptive effect depends on the hormonal status of the patient. 
 
64
   
In conclusion, we identified sex differences in the tumor-induced expression of 
TRPA1 and TRPM8 in bone tumor-bearing mice and sex differences in cold 
sensitivity. The phase of the estrus cycle affects tumor-induced mechanical 
allodynia in intact females and estradiol replacement affects tumor-induced 
mechanical allodynia in an opposite manner between males and females.  
Menthol is antinociceptive in tumor-induced pain, an effect that depends on 
estrogen in females, but is attenuated by estrogen in males.  With the 
development of TRPA1 antagonists to abate pain and the use of TRPM8 
agonists and antagonists for cold pain therapies it is prudent to consider sex and 
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Figure 1:  Estrogen a???cts tumor-induced mechanical allodynia in both 
males and females.  Von Frey testing of the hind paw was used to assess 
tumor-induced mechanical allodynia (A) in males (n=15) and females 
(n=20) over time, (B) in females in the proestrus/estrus phase (n=9-14) 
compared to those in diestrus (n=6-11), (C) in OVX (n=4) and OVX+E 
females (n=4), (D) in ORCH males (n=5) and ORCH+E males (n=5) .  
The group means (±SEM) of the data are expressed as percent of the 
response.  Data were analyzed using repeated measures analysis of 
variance (ANOVA) followed by post hoc analysis using Tukey’s HSD test 
where signi???ance is indicated by and asterisk (P<0.05).
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Figure 2:  Cold nociceptive sensitivity is greater in females than males, 
but is una???cted by estrogen.  Cold plate thresholds were used to assess 
the degree of thermal hyperalgesia (A) in females compared to males, 
(B) during the estrous cycle, (C) in OVX and OVX+E females , and (D) in 
ORCH and ORCH+E males.  The group mean (±SEM) re???cts the same n 
as in ???ure1  Data were analyzed statistically as in Figure 1.




































Figure 3: Tumor-induced TRP mRNA expression di???rs in males and females.  
Data indicate the relative expression of lumbar DRG TRPA1 (A) and TRPM8 (B) 
mRNA at PID 21.  Lumbar DRG mRNA was assessed by comparing tumor-
bearing animals to saline-injected animals of the same hormone status.  The 
fold change is shown as group means (±SEM).  Data were analyzed using a 
one-way ANOVA with Tukey HSD post hoc test where signi???ance is 
indicated by and asterisk (P<0.05).  For sample numbers, refer to the legend 
for Figure 1.











































Figure 4:  Menthol, a TRPM8 agonist, reduced tumor-induced nociception.  
The e???ct of plantar application of menthol on mechanical allodynia (A) 
and thermal hyperalgesia (B) was assessed in all groups.  Antinociceptive
 responses were measured by subtracting pre-treatment nociceptive 
responses from the post-treatment assessments.  Data are expressed as 
the mean (±SEM) changes in percent response (%) to a von Frey ???er and 
in the cold plate thresholds (sec).  Data were analyzed statistically as in 
??gure 3.
Figure 4:  Menthol reduces tumor-induced nociception
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Chapter 4 
Sex differences and estrogen effects on TRPV1 expression and antagonism in a 
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Introduction 
The study of sex differences has become of utmost importance for understanding 
and abating pain for numerous human health conditions and disease states [11; 
47; 48; 57; 94].  Women self-report greater anxiety towards anticipated pain 
compared to their male counterparts [55] and have a higher prevalence of 
several chronic pain conditions and inflammation-mediated disorders including 
fibromyalgia, arthritis, migraine, temporomandibular disorders, and irritable bowel 
syndrome [48; 49].  Moreover, in experimentally-induced human pain testing, 
evidence exists for sex differences in sensitivity and in the response to 
analgesics [12; 14; 36; 47; 55; 79; 94; 145].  Basic and clinical studies are just 
beginning to delineate sex differences in cancer pain.  In this regard, women are 
more likely to experience enhanced cancer pain due to reduced prescription of 
analgesics [93] and subsequently reduced quality of life compared to their male 
counterparts [56].  Thus, additional research is needed to clarify the mechanisms 
for sex differences to facilitate new treatment modalities that improve cancer pain 
management for both men and women.    
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Malignant bone tumors occur in patients with primary bone cancer and more 
commonly as distant metastases from non-bone primary tumors, such as breast, 
prostate, and lung cancer.  As tumors grow they invade both soft and bony tissue 
changing the chemical milieu and provoking inflammatory cell responses, thus 
sensitizing nociceptors from being exclusively noxious stimulus detectors to 
detectors of innocuous inputs [60; 61; 146].  A number of cancer pain 
investigations have focused on members of the transient receptor potential (TRP) 
ion channel family [108; 109], since these receptors detect a diverse range of 
mechanical, chemical, and thermal stimuli and transduce both innocuous and 
noxious stimulus into action potentials in primary afferent nociceptors [34; 82; 
100].  The first TRP channel discovered in mammalian sensory neurons was the 
vanilloid-1 (TRPV1) channel, which serves as the receptor for capsaicin, the 
pungent ingredient in hot chili peppers, and also acts as a key receptor for 
noxious physical heat (>42 °C) [24] and mechanical stimulation [91; 142; 150].   
In male rodent models of bone cancer pain, increased nociceptive behavior is 
due to increased TRPV1 expression and activation in DRG neurons [70; 97; 153].  
Conversely, in knock-out mice, TRPV1-/-, these behaviors are significantly 
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attenuated (reviewed in [82]).   Several clinically useful TRPV1 antagonists and 
potent agonists have been synthesized and evaluated in animal models of cancer 
pain (reviewed in [132]).  These results suggest that the TRPV1 channel has a 
role in the integration of nociceptive signaling in chronic pain states, like bone 
cancer, and that the modification of TRPV1 might be effective in attenuating 
tumor-induced pain which is typically difficult to treat. 
 
Whether sex differences in cancer pain are due to the effects of sex hormones on 
TRPV1 has yet to be delineated.  Based on the role of TRPV1 receptors in pain 
and the greater sensitivity to cancer pain in females than males, estrogen may 
influence TRPV1 receptor expression and activity.  In the present study, we 
hypothesized that sex steroid hormones alter tumor-induced transcription of 
TRPV1 channels in DRG neurons as well as influence the response of TRPV1 
receptors to the TRPV1 selective antagonist, JNJ-17203212.  Utilizing a mouse 
model of bone cancer pain [141], we compared intact, gonadectomized, and 
estradiol-replaced males and females to delineate gonadal hormones effect on 
tumor-induced TRPV1 receptor expression and nociception.  To determine if sex 
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hormones, specifically estradiol, affect receptor antagonist analgesia we 
examined the antinociceptive effects of a TRPV1 antagonist on tumor-induced 





Adult male and female C3H/He mice (8-10wks of age) were obtained from 
National Cancer Institute.  Mice were housed under a 12-hour light/dark 
photoperiod with food and water available ad libitum.  All animal care was 
performed and supervised by the University of Minnesota Research Animal 
Resources.  All procedures were reviewed and approved by the University of 
Minnesota Institutional Animal Care and Use Committee. 
 
Surgery 
To determine the effects of gonadal steroids, specifically estradiol, on 
nociception, animals were gonadectomized (females: OVX, males: ORCH) with 
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half receiving estrogen replacement (OVX+E, ORCH+E).  Surgical procedures 
were carried out under aseptic conditions according to “Principles of Laboratory 
Animal Care” (NIH publication, 8th Ed, revised 2011). Mice were placed in an 
enclosed chamber and anesthetized with isoflurane in preparation for 
gonadectomy. When the animal did not respond to paw pinch, it was removed 
from the chamber and fitted with a facemask that continuously delivered 1–2% 
isoflurane in an air/oxygen mixture throughout the surgery.  On the day of 
surgery, animals were either gonadectomized, gonadectomized and given 
silastic-hormone implant, or subjected to sham surgery.  Briefly, ovariectomized 
females (OVX) had a 5 mm dorsal incision made through the skin and two lateral 
incisions made through the left and right abdominal muscle wall.  Ligatures were 
placed around the oviduct and the ovary was removed above the ligation.  The 
muscle wall was closed with silk sutures and the skin closed with staples.   
 
Orchectomized males (ORCH) had a 1 cm median incision through the scrotum 
and small incisions made through cremaster muscles to expose the testes.  
Ligatures were placed around the vas deferens and the testes were removed 
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above the point of ligation.  Skin and muscles were closed with silk sutures. 
Sham surgery animals received identical surgical procedures but without the 
ligation and removal of the gonadal organs. 
 
For chronic estrogen replacement in OVX+E and ORCH+E animals, a Silastic-
implant  (i.d.: 1.57mm, o.d.: 3.18mm; Dow Corning, MI) containing 3 mg of 
crystalline 17β-estradiol (Sigma Chemical Co, St. Louis, MO) sealed at both ends 
with silicone medical adhesive was prepared and allowed to cure over night.  
During gonadectomy surgery, the Silastic implant was placed subcutaneously 
(s.c.) through a small dorsal incision in the back.  Previous studies have 
determined that such implants produce high physiologic levels of serum estrogen 
in the circulation [30; 106].   
 
Cell culture and implantation 
Cell culture and implantation were performed per Cain et al. [21]. Briefly, mice 
were placed in an enclosed chamber and anesthetized in preparation for cell 
implantation. When the animal did not respond to paw pinch, it was removed 
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from the chamber and fitted with a facemask that continuously delivered 1–2% 
isoflurane in an air/oxygen mixture throughout the implantation. NCTC clone 
2472 connective tissue cells were obtained from American Type Cell Culture.  
The cells were grown to confluence in 75 cm2 flasks in NCTC 135 medium, pH 
7.35, 10% horse serum, and passed one time weekly by a 1:4–6 split ratio.  The 
cells were then counted with a hemacytometer, pelleted, resuspended in PBS for 
implantation in a concentration of 2 x 105 cells/10µl.  Cells were injected 
unilaterally into and around the calcaneus bone in a volume of 10µl, whereupon 
the syringe was used both to bore through the calcaneus bone (proximal to 
distal) and inject the cells as the needle was withdrawn. This implantation 
protocol was derived from a femur skeletal metastasis model that has been used 
to study the cellular and biochemical mechanisms mediating bone destruction at 
the tumor site [29]. 
 
Measurement of hyperalgesia  
On the day of implantation, baseline values for mechanical and thermal 
sensitivity were determined for each animal randomly assigned to the cell-
77
   
implanted or saline groups, prior to hindpaw implantation of fibrosarcoma cells.  A 
3.4 milliNewton (mN) von Frey monofilament was used because the responses of 
tumor-bearing C3H/He mice to this monofilament are reproducible and 
sufficiently large to allow detection of dose-dependent attenuation by analgesics 
or antagonists [21; 141].  Testing was repeated throughout the time course of 
each study.  Briefly, animals were placed on a wire mesh platform, covered with 
a hand-sized container, and allowed to acclimate to their surroundings for a 
minimum of 30 min before testing. The monofilament was applied 10 times to the 
point of bending on the plantar surface of each hindpaw.  The number of vigorous 
responses to the monofilament were counted and expressed as a percentage of 
stimuli giving rise to a withdrawal response (percent response frequency).  
 
Hot plate response latencies were obtained from mice placed on a heated plate 
(52±2°C; Technilab Instruments, Inc., Pequannoch, NJ).  Latency to hind paw 
withdrawal/lift from the surface not related to general movements was determined 
as the end point.  Mice were tested for a maximum of 30 s for each session.  
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Data was recorded as threshold in s.  There was at least a 30-min rest between 
mechanical and thermal testing.   
 
Following the hot plate test, ankle widths were obtained to determine tumor size.  
The tumor size was measured with a caliper and expressed in millimeters (mm).  
Tumor growth was determined by subtracting the baseline measurement from the 
measurement on that post implantation day.   While tumor growth was evident, 
there were no sex differences in tumor growth between male and female C3H 
mice injected with NCTC 2472 fibrosarcoma cells into the hind paw tumor (Figure 
1A) nor were there any differences in tumor growth among gonadal-hormone 
groups when compared to intact mice (Figure 2A).  In saline-injected control 
animals the ankle width and mechanical nociceptive sensitivity did not change 
over the course of the experiments (data not shown). 
 
Treatment with the TRPV1 antagonist 
In a separate group of both fibrosarcoma-injected and naïve C3H mice, we 
injected the mice with JNJ-17203212, a TRPV1 selective antagonist (30 mg/kg, 
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s.c., Tocris Bioscience, Bristol, UK), dissolved in 120µL of Kollipher HS-15 
(BASF Corporation, Florham Park, NJ) and 680 µL of 5% dextrose or an 
equivalent volume of vehicle alone.   Ghilardi et al. have shown previously that 
the dose used in the current study causes no observable adverse effects in 
movement performance, general activity, and body weight [53].  Antagonist 
behavioral testing was done on PID 21 when there was significant tumor growth 
and hyperalgesia.  Prior to antagonist or vehicle injection, animals were tested 
for von Frey response and hot-plate latency as described above (pre-treatment).  
A one-time injection of antagonist was administered s.c. and approximately 1h 
later von Frey response was measured; 30 min after which, hot-plate latency 
was measured (post-treatment).  The difference between the von Frey and hot-
plate latency pre-treatment and post-treatment were calculated.  Administration 
of the vehicle in a separate group of tumor-bearing mice did not produce any 
adverse effects (data not shown).  Administration of either the antagonist or the 
vehicle did not produce any effects in naïve animals (data not shown). 
 
Estrous cycle determination 
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Stage of the estrous cycle for individual female mice was determined using 
vaginal cytology.  Samples were collected using swabs moistened with sterile 
saline; contents were smeared onto a slide and allowed to completely air-dry.  
Slides were placed in 95% EtOH for 5 min, and then stained in cresyl violet for 
20-30 min.  Slides were rinsed with water, allowed to air dry, and examined 
microscopically.  Based on the cytologic profile, mice were deemed to be in one 
of two hormones states: proestrus/estrus (high hormone milieu with a 
predominance of nucleated epithelial cells or cornified squamous cells) or 
diestrus (low hormone milieu with a predominance of leukocytes) [8; 22].  
 
Quantification of mRNA by real-time PCR 
Dorsal root ganglia L1–L5 were isolated from mice, placed in RNAlater (Qiagen, 
Valencia, CA) and stored at -80°C. Total RNA was isolated from DRG samples 
using RNeasy Lipid Tissue Mini Kits (Qiagen, Valencia, CA). RNA was reverse 
transcribed into cDNA using QuantiTect RT-PCR kits (Qiagen, Valencia, CA) as 
per the manufacturer’s instructions. Real-time PCR studies were performed with 
Perfecta SYBR Green Master Mix (Quanta, Gaithersburg, MD) using 
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Stratagene's Mx3000P Real-Time PCR Systems (Agilent Technologies, Santa 
Clara, California). 
  
Each cDNA sample was run in triplicate for the murine TRPV1 receptor and the 
reference gene (β-actin).  Primers were developed using the NCBI Primer-BLAST 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) and synthesized at the 
BioMedical Genomics Center at the University of Minnesota.  Primer pair 
sequences were as follows: TRPV1 receptor (GenBank Accession number 
NM_001001445.1) forward primer 5’- CCGAAGTGGAGCAGAAGAAG -3’ and 
reverse primer 5’- GATCCTTGCGACATGGTCAAG -3’; β-actin (NM_007393.3) 
forward primer 5’- AGGAGTACGATGAGTCCGGC -3’ and reverse primer 5’- 
GCAGCTCAGTAACAGTCCGC -3’.  The ratio of fold change in expression of the 
mRNA of interest for each sample was calculated by normalization of cycle 
threshold (Ct) values to β-actin.  Using the equation derived by Pfaffl [103] to 
correct for potential differences in PCR primer efficiencies between the target and 
reference genes, Ct values for tumor-bearing animals were normalized to the 
averaged Ct values calculated for saline-injected counterparts; Ct values for 
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saline-injected animals were normalized to the averaged Ct values calculated 
from their own group.  The fold change was then derived from the differences 
between the Ct values (2(-del del Ct)). 
 
Statistics 
Results were analyzed with JMP software (v.9.0.0 Copyright © 2010 SAS 
Institute Inc., Cary, NC, USA). Values were represented as mean ± SEM 
(standard error of the mean).  The mean frequency of withdrawal responses to 
mechanical stimuli and mean latency to respond for thermal stimuli were 
analyzed by repeated-measures ANOVA with Tukey-Kramer HSD post hoc 
comparison.  Between group comparison of the mean frequency of withdrawal 
responses to mechanical stimuli and mean latency to respond for thermal stimuli 
were analyzed by one-way ANOVA with a Tukey-Kramer HSD or an unpaired 
Student’s t-test post hoc comparison.  Between group comparison of the relative 
mRNA expression were analyzed by one-way ANOVA with a Tukey-Kramer 
HSD.  Bivariate analysis was used to evaluate correlational data between relative 
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mRNA expression and hyperalgesia responses.  A value of p < 0.05 was 
considered statistically significant. 
 
Results 
Mechanical allodynia was similar in both males and females (F(1,28)=0.0338, 
p=0.339) as responses to the von Frey fiber increased similarly over time 
(F(9,20)=39.48, p<0.0001, Fig 1B).  There was a greater tumor-induced mechanical 
allodynia in females during the proestrus/estrus phases of the estrous cycle than 
during diestrus (F(1,13)=0.369, p=0.047, Fig 1C).  These differences started at PID 
15 and were most robust at PID 21.  Hot plate latencies were similar in both 
males and females (F(1,18)=0.015, p=0.607, Fig 1D) with no detectable change 
over time (F(9,10)=1.74, p=0.20).  The phase of estrous also did not affect thermal 
hyperalgesia (F(1,6)=0.012, p=0.917, Fig 1E).  These results indicate that while 
tumor-induced thermal hyperalgesia does not develop, estrogen enhances 
tumor-induced mechanical allodynia.   
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Given the robust difference in mechanical allodynia at PID 21, we focused our 
remaining studies  on this time-interval.  To examine estradiol’s effect on tumor-
induced nociception, we gonadectomized one group of females (OVX) and 
replaced 17β-estradiol (OVX+E) in half of these mice. Estradiol replacement 
(OVX+E) increased tumor-induced mechanical allodynia compared to OVX alone 
(p=0.033, Fig 2B).  Because sex steroid hormones reduce nociception in males 
[54; 127], we also examined the effect of gonadectomy (ORCH) and 17β-
estradiol replacement (ORCH+E) on tumor-induced nociception in males.  There 
estradiol replacement (ORCH+E) reduced mechanical allodynia compared to 
ORCH alone (p=0.0005, Fig. 2B).  Neither tumor growth (Fig 2A) nor hot plate 
latency (Fig 2C) was influenced by gonadectomy and estradiol replacement in 
either males or females (Fig 2C).  These results indicate that while there is no 
difference between intact males and females in sensitivity to mechanical pain, 
estrogen increases mechanical nociception in females, but decreases it in males.  
 
TRPV1 expression increases in DRG neurons of male mice [70] and male rats 
[121] with bone cancer.  However, it is not known whether hormone status of the 
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tumor-bearing animal effects TRPV1 expression.  We found TRPV1 mRNA 
expression was greater in tumor-bearing intact females during proestrus/estrus 
than during diestrus; (Fig 3A, F(5, 47)=3.035, p=0.0187).  This suggests that 
increases in circulating estrogen increase tumor-induced TRPV1 mRNA 
expression.  Conversely, OVX females have greater TRPV1 expression than 
OVX+E females and ORCH+E males, suggesting that replacement of estradiol 
decreases tumor-induced TRPV1 expression.  These results indicate that the 
availability of estrogen can affect tumor-induced expression of TRPV1 in an 
opposite manner. 
 
Using correlational analyses, we found that in intact tumor-bearing females, 
TRPV1 positively correlated with tumor-induced mechanical allodynia (R=0.602, 
p=0.005, Fig 3B).  Conversely, there was no correlation between these 
parameters in intact tumor-bearing males (R=0.047, p=0.868).  There were no 
similar correlations between TRPV1 and mechanical allodynia in 
gonadectomized and gonadectomized with 17-estradiol replacement animals 
(data not shown).  Moreover, there was no correlation between TRPV1 and 
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thermal hyperalgesia (data not shown).   Taken together, these relationships 
suggest a link between tumor-induced mechanical allodynia and changes in 
mechanical sensitivity of DRG cells to estrogen in intact females. 
 
In all tumor-bearing animals, acute treatment with 30 mg/kg s.c. of JNJ-
17203212, a TRPV1 receptor antagonist, reduced von Frey fiber responses (Fig 
5A).  The hormonal status of the mice is a factor in JNJ-17203212-induced 
mechanical antinociception (F(5,30)=8.303, p=0.0003) as females in the 
proestrus/estrus phase of the estrous cycle  have greater mechanical 
antinociception than females in the diestrus phase, and greater than intact males, 
OVX, OVX+E, and ORCH+E mice.    Conversely, ORCH+E males had 
diminished antinociception in response to JNJ-17203212 compared to intact 
females, OVX+E, and ORCH mice (Fig 5A).   TRPV1 receptor antagonism 
induced thermal analgesia with no influence by hormonal status or sex of the 
experimental group (Fig 5B).  JNJ-17203212 had no effect in naïve or non-tumor-
bearing animals (data not shown).  These results suggest that estrogen is 
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necessary for JNJ-17203212 to have an antinociceptive effect in tumor-bearing 
female mice, but estrogen can inhibit this antinociceptive effect in males. 
 
Discussion 
In contrast to inflammatory models of pain showing that females are also more 
sensitive to mechanical hyperalgesia than males [32; 40], there are no sex 
differences in the intensity of mechanical hyperalgesia in an osteosarcoma model 
of bone cancer pain [123].  Consistent with this, in our animal model of 
fibrosarcoma bone cancer pain, males and females have the same sensitivity to 
mechanical and thermal (heat) nociception.  However, estrogen, either released 
endogenously during the estrus cycle or delivered after gonadectomy, increased 
von Frey fiber responses in females but decreased them in males.  Hot-plate 
hyperalgesia did not develop in tumor-bearing animals, consistent with previous 
findings indicating that tumor-bearing mice do not develop thermal hyperalgesia 
until 4 weeks (28 days) post implantation [92], well beyond the PID 21 that we 
examined.   
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In models of bone cancer pain, TRPV1 expression and activation is increased in 
DRG neurons of males [59; 70; 97; 135; 153].  In our model of fibrosarcoma bone 
cancer pain, we are the first to demonstrate that females also have an increase in 
TRPV1 mRNA expression in DRG neurons innervating the hindpaw similar to 
their male counterparts.   During the estrous cycle, nociception in other models of 
pain [37; 63] and TRPV1 sensitivity [101] both vary.  We also found that the 
estrous cycle influences fibrosarcoma bone cancer pain as TRPV1 receptor 
mRNA expression differed between the two estrous cycle groups.  Females in 
diestrus have lower TRPV1 mRNA expression whereas those in proestrus/estrus 
express nearly a 5-fold increase in TRPV1 mRNA expression.  Conversely, 
gonadectomy increased TRPV1 mRNA in females, while estrogen replacement 
reversed this.  The difference in TRPV1 mRNA expression between intact and 
gonadectomized females could be due to the influence of progesterone or other 
sex steroid hormones (e.g. leuteinizing hormone, follicle stimulating hormone).  
We show that estradiol replacement does not affect the expression of TRPV1 in 
males and females, adding to the suggestion that other sex steroid hormones 
influence TRPV1 mRNA expression.  This phenomenon of less TRPV1 mRNA 
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expression, but greater mechanical sensitivity in OVX+E females compared to 
OVX females could be due to a down-regulation of TRPV1 receptors as a result 
of their enhanced activity.  As mechanical allodynia increased, TRPV1 mRNA 
decreased, yet correlational analysis indicated intact female mechanical allodynia 
is positively correlated with TRPV1 expression. 
 
In models of bone cancer pain, TRPV1 receptor antagonists reduce cancer pain 
in male rodents [53; 95-97; 121; 135].  Specifically, JNJ-17203212, attenuates 
both ongoing and movement-evoked nocifensive behaviors in male mice with 
bone cancer pain [53].  In our model of fibrosarcoma bone cancer pain, 
antagonism of the TRPV1 receptor also attenuated mechanical allodynia in 
females but had no effect on thermal hyperalgesia in both sexes.  The efficacy of 
JNJ-17203212 appeared to be estrogen-dependent as JNJ-17203212 reduced 
mechanical pain during proestrus and estrus but attenuated mechanical 
antinociception by the addition of estrogen in ORCH males.   It is known that 17β-
estradiol can act directly on DRG cell bodies to reduce capsaicin-induced TRPV1 
receptor activation [148].   Taken together, our results suggest that JNJ-
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17203212 is a potential analgesic for tumor-induced nociception, but the 
antinociceptive effect depends on the recipients’ hormonal status. 
 
In conclusion, estrogen affects tumor-induced expression of TRPV1 and the 
phase of the estrus cycle determines the magnitude of tumor-induced mechanical 
allodynia in intact females.  Estradiol replacement affects tumor-induced 
mechanical allodynia in an opposite manner in males than in females.  JNJ-
17203212 is antinociceptive on tumor-induced pain, an effect that depends on 
estrogen in females, but is attenuated by estrogen in males.  Future use of 
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Figure 1: Tumor growth was measured by ankle width (A) in males (n=15) and 
females (n=20) over time. Von Frey testing of the hind paw was used to assess 
tumor-induced mechanical allodynia (B) in males and females over time, (C) in 
females in the proestrus/estrus phase (n=9-14) compared to those in diestrus 
(n=6-11). The group means (±SEM) of the data are expressed as percent of the 
response. Hot plate latency were used to assess the degree of thermal hyper-
algesia (D) in females compared to males and (E) during estrous cycle. The 
group means (±SEM) of the data are expressed as latency in seconds. Data were 
analyzed using repeated measures analysis of variance (ANOVA) followed by 
post hoc analysis using Tukey’s HSD test where signi???ance is indicated by an 
asterisk (P<0.05).
Figure 1: Estrous cycle a???cts mechanical allodynia but not 





















































Figure 2:  Tumor growth was measured by ankle width (A) in OVX (n=4), 
OVX+E (n=4), ORCH (n=5), ORCH+E (n=5) at post implantation day (PID) 
21. Von Frey testing of the hind paw was used to assess tumor-induced 
mechanical allodynia (B) and hot plate latency was used to assess the 
degree of thermal hyperalgesia (C) in OVX, OVX+E, ORCH, ORCH+E at 
PID 21. The group means (±SEM) of the data are shown. Data were 
analyzed using a One-Way ANOVA followed by post hoc analysis using 
Tukey’s HSD test. Hash tag (#) indicates OVX+E is signi???ant compared 
to ORCH+E and OVX where sign?????nce indicated by an asterisk (*) 
indicates ORCH is signi???ant compared to ORCH+E and OVX (P<0.05).
Figure 2: 17?????estradiol replacement e??ects nociception in 















































R=0.602 p=0.005* n=20 R=0.047 p=0.868 n=15
?
Figure 3: Data indicate the relative expression of lumbar DRG TRPV1 (A) mRNA at 
PID 21. Lumbar DRG mRNA was assessed by comparing tumor-bearing animals 
to saline-injected animals of the same hormone status. The fold change is shown 
as group means (±SEM). Data were analyzed using a one-way ANOVA with Tukey 
HSD post hoc test. Hash tag (#) indicates females in the diestrus phase of the 
estrous cycle are signi????nt compared to proestrus/estrus females, intact males, 
OVX, and ORCH, where signi???ance indicated by an asterisk (*) indicates OVX is 
signi????nt compared to OVX+E and ORCH+E (P<0.05). For sample numbers, refer 
to the legend for Figure 1. Bivariate correlational analyses were used to determine 
the statistical signi????nce of the relationship between tumor-induced mechanical 
allodynia and TRPV1 mRNA expression (B) in intact females and (C) in intact males. 
Signi???ance is indicated with an asterisk (P<0.05)
Figure 3: Estrous cycle and estrogen a???cts the tumor-induced 















































Figure 4:  The e???ct of subcutaneous injection of JNJ-17203212 on 
mechanical allodynia (A) and thermal hyperalgesia (B) was assessed 
in all groups. Antinociceptive responses were measured by subtracting 
pre-treatment nociceptive responses from the post-treatment assessments. 
Data are expressed as the mean (±SEM) changes in percent response (%) to 
a von Frey ???er and in the hot plate thresholds (sec). Data were analyzed 
using a one-way ANOVA with Tukey HSD post hoc test. Hash tag (#) indicates 
females in proestrus/estrus phase of the estrous cycle are signi???ant compared 
to intact males, diestrus females, OVX, OVX+E, and ORCH+E where signi???ance 
indicated by an asterisk (*) indicates ORCH+E males are signi???ant compared to 
intact females, OVX+E, and ORCH (P<0.05).
Figure 4: JNJ-17203212, a TRPV1 antagonist, reduces 
                  tumor-induced hyperalgesia. 
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Chapter 5 




   
Summary 
This thesis provides several important and novel findings related to tumor-
induced nociception and the effects of sex steroid hormones (see Summary 
Table).  First, the stage of the estrous cycle affects tumor-induced mechanical 
hyperalgesia with females in diestrus exhibiting reduced mechanical hyperalgesia 
compared to females in proestrus/estrus.  Second, while it is known that TRPV1 
receptor expression and activation is increased in DRG neurons of tumor-bearing 
males [59; 70; 97; 135; 153], we are the first to demonstrate that females also 
have an increase in TRPV1 receptor mRNA expression in DRG neurons 
innervating the hindpaw.  Moreover, we are the first to show males and females 
differed in their tumor-induced expression of TRPA1 and TRPM8 receptor mRNA 
in DRG neurons.  Third, using a known TRPV1 receptor antagonist, we were able 
to induce analgesia in tumor-bearing males and demonstrate that females’ 
analgesic response is dependent upon estrogen.  Moreover, using a known 
TRPM8 agonists, the present study is the first to examine and show an 
antinociceptive effect on tumor-induced pain.   
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Sex differences in tumor-induced mechanical allodynia manifested in our model 
of bone cancer pain with females in diestrus phase of the estrus cycle less 
sensitive to mechanical stimulation than females in the proestrus/estrus phase 
and males.  When the cyclical effects of female sex steroid hormones were 
controlled with gonadectomy (OVX), OVX females have mechanical allodynia 
that were similar to females in the diestrus phase of the estrous cycle.  When 
17β-estradiol was replaced (OVX+E), mechanical allodynia was greater in 
OVX+E which is similar to that observed in females in the proestrus/estrus phase 
of the estrous cycle.  These results reveal that tumor-induced allodynia fluctuates 
with the phase of the estrous cycle.  Moreover, our results indicate that female 
sex steroid hormones, specifically estradiol, enhances, rather than inhibits, 
tumor-induced mechanical allodynia in females.  
 
In other models of pain, sex steroid hormones in males reduce nociception [54; 
126].  Thus, we examined the effect of tumor-induced nociception in 
gonadectomized males (ORCH) whose circulating sex steroid hormones would 
be diminished.  Consistent with previous findings, ORCH males have greater 
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tumor-induced mechanical allodynia compared to intact counterparts.  17β-
estradiol replacement (ORCH+E) reduced mechanical allodynia similar to that 
observed in females with reduced sex steroid hormones (diestrus/OVX).  This 
suggests that estrogen plays an opposite role in males and females with tumor-
induced nociception.  Furthermore, these findings suggest that male’s circulating 
hormones are necessary for reduced tumor-induced mechanical allodynia and 
that estrogen plays a role in this phenomenon.     
 
Sex differences in tumor-induced cold hyperalgesia manifested in our model of 
bone cancer pain with females becoming more sensitive than males.  Although 
we show tumor-induced mechanical allodynia is sensitive to the effects of 
estrogen, cold-plate hyperalgesia was relatively insensitive to changes in 
estrogen.  Although tumor-bearing females were more sensitive to the cold plate, 
cold-plate sensitivity was not attenuated by the estrous cycle or the addition of 
estrogen to gonadectomized mice.  
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TRPV1, TRPA1, and TRPM8 receptors transmit noxious thermal, mechanical 
and chemical sensitivities that contribute to pain hypersensitivity associated with 
peripheral inflammatory and neuropathic pain states [34; 109; 130].  In this thesis 
we show both males and females have an increase in TRPV1 mRNA in DRG 
neurons innervating the tumor-bearing hindpaw.  Moreover, we found that the 
estrous cycle influences TRPV1 receptor mRNA expression as females in 
diestrus have lower TRPV1 receptor mRNA expression than those in 
proestrus/estrus, where the expression is increases nearly 5-fold.   TRPV1 
receptor is activated by mechanical stimulation in rodent models of inflammatory 
pain [91; 142].  In our model of bone cancer pain, tumor-induced mechanical 
allodynia was similar between males and females, and not surprisingly, TRPV1 
receptor mRNA expression was also similar.  However, when the phase of the 
estrous cycle was taken into account, tumor-induced mechanical allodynia was 
lower in females during diestrus, which paralleled TRPV1 receptor mRNA 
expression that is also significantly lower during diestrus.  These findings would 
suggest the difference in tumor-induced mechanical allodynia during the phases 
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of the estrous cycle are due, in part, to the fluctuations in expression of the 
TRPV1 receptor expression. 
 
TRPA1 receptor is considered a thermo-TRP that is gated by noxious cold [3; 76; 
78] and has been shown to be involved in cold-induced nociceptor behavior in 
mice [67].  TRPM8 receptor is another thermo-TRP involved in both cooling-
mediated analgesia and cold hypersensitivity after injury in rodent models of pain 
[7; 31; 42; 131].  In our model of bone cancer pain, males and females differed in 
their expression of cancer-induced changes in TRPA1 receptor and TRPM8 
receptor expression, where intact males expressed more TRPA1 receptor and 
intact females express more TRPM8 receptor.  Unlike the TRPV1 receptor, the 
phase of the estrous cycle did not affect the expression of TRPA1 receptor and 
TRPM8 receptor mRNA.  Females were more sensitive to tumor-induced cold 
hyperalgesia than males.   With TRPM8 receptor increasing in tumor-bearing 
females, this would suggest that TRPM8 receptor corresponds with tumor-
induced cold hyperalgesia in females.   
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The use of TRP agonists and antagonists to abate peripheral and central 
neuropathic pain has been analyzed in rodent models of pain [108].  We 
examined the analgesic effects of a TRPV1 receptor-selective antagonist and a 
TRPM8 receptor-selective agonist on bone tumor-induced nociception.   JNJ-
17203212, a TRPV1 receptor-selective antagonist attenuates both ongoing and 
movement-evoked nocifensive behaviors in male mice with bone cancer pain [53].  
In our model of fibrosarcoma bone cancer pain, antagonism of the TRPV1 
receptor also attenuated mechanical allodynia in both males and females.  The 
efficacy of JNJ-17203212 appeared to be estrogen-dependent as JNJ-17203212 
reduced mechanical pain more during proestrus/estrus than during diestrus.  
Menthol, a TRPM8-selective agonist, is a natural compound of plant origin that is 
analgesic at low concentrations [38; 66; 136; 143].   To our knowledge, the 
present study is the first to show an antinociceptive effect of topical menthol on 
tumor-induced pain.  The efficacy of menthol appears to be estrogen dependent 
as gonadectomized females (OVX) have less analgesia than females with 17β-
estradiol replacement.   Taken together, our results suggests JNJ-17203212 and 
menthol are potentially novel pharmaceutical compounds that could be used for 
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the treatment of bone cancer pain.  With that said, our work also suggest that the 
antinociceptive effect will depend on the hormonal status of the patient, which 
needs to be taken into account. 
 
Conclusions 
Using a well-established mouse model of bone cancer pain [141], and we 
hypothesized that that estrogen would potentiate cancer pain by altering tumor-
induced transcription of TRP receptors and their function.  We documented that 
sex differences exist in tumor-induced mechanical allodynia and cold-
hyperalgesia.  We also showed that estrogen influences tumor-induced sensitivity 
making females more sensitive to mechanical allodynia, whereas in males is 
makes them less sensitive.  Conversely, estrogen did not effect thermal 
hyperalgesia, but instead the sex of the animal was most important with females 
having more tumor-induced cold sensitivity than males.  We delineated that both 
males and females up-regulate TRPV1 receptor mRNA in lumbar DRGs, but 
differ in their expression of TRPM8 receptor and TRPA1 receptor mRNA with 
tumor-bearing females up-regulating TRPM8 receptor only.  Moreover, 
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antagonists of TRPV1 receptor and agonists for TRPM8 receptor were effected 
by estrogen as females in proestrus/estrus phase of the estrous cycle or with 
estrogen replacement exhibited the greatest analgesia.  Overall, we prove our 
hypothesis that estrogen potentiates cancer pain, but also show that it attenuates 
pain the males.  We also prove that estrogen alters tumor-induced transcription 
of TRP receptor mRNA and alters the activity of selected TRPV1 receptor 
antagonist and TRPM8 receptor agonists.  Our findings suggest that estrogen 
potentiates tumor-induced nociception through its effects on TRP receptors.  
 
This work adds to the growing body of evidence that sex steroid hormones 
affect tumor-induced pain at the behavioral and the molecular level of pain 
signaling.  Future models of pain and analgesic research should include both 
sexes and make note of the phases of the estrous cycle in females.  The next 
steps that are required to build on this body of work include testing of other 
analgesic drugs to determine if there are sex differences or estrogen effects on 
drug efficacy in bone the treatment of bone cancer pain.  It will also be 
important to test other types of cancer (pancreatic, ovarian, prostate, breast, 
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etc) to determine if sex hormones affect tumor-induced pain.  Clearly more 
research is necessary since cancer, second only to heart disease in cause of 
death in Americans, has a nociceptive component that will effect many lives.   
Since we are just beginning to understand how sex hormones and sex 
differences play key roles in the generation and perception of pain, it is critical to 
incorporate sex difference as part of the basic research paradigm to uncover 
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